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ABSTRACT 
Obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease 
(COPD) or Overlap syndrome has been shown to occur anywhere between 1-40% in 
population and clinic studies. Subjects with overlap syndrome are at increased risk of 
cardiovascular disease mortality than subjects with either condition alone. It has been 
hypothesized that hypoxic induced inflammation occurs in both conditions however 
research is limited as to the relationship between OSA and subclinical cardiovascular 
disease and the affect COPD has on this relationship.  
Several studies have looked at the association between OSA and COPD with 
conflicting results. A limitation to this research is defining COPD strictly by pulmonary 
function. Additionally there is inadequate research evaluating the relationship between 
OSA and subclinical atherosclerosis specifically examining the influence of various 
pulmonary abnormalities.  
The overall goal of the proposed research is to explore the pathway between OSA 
and subclinical atherosclerosis with measures of calcification from coronary and thoracic 
arteries and determine if these relationships are altered by pulmonary abnormalities. In 
addition, we evaluated the validity of self-reported OSA and the utility of Berlin sleep 
questionnaire in a COPD population. Multivariable regression analyses were utilized to 
evaluate these relationships. OSA was found to not be related to pulmonary function 
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reduction (GOLD stages 2-4) or Emphysema however, there was a significant 
relationship with chronic bronchitis. In evaluating the association of OSA with 
calcification measures, we found a significant upward trend of prevalent OSA by 
increased severity of CAC (p<0.05) and there was an independent relationship between 
OSA and CAC independent of functional reduction and emphysema in adjusted models.  
Examining the differences in re-saturation time we found that subjects with OSA and 
Emphysema had significantly greater re-saturation time than subjects with OSA alone. 
When evaluating all relationships using self-reported OSA, the results were 
ameliorated. It was also determined that the Berlin sleep questionnaire does not 
accurately identify OSA in a COPD population. These are the first studies to fully 
examine the relationships between OSA and pulmonary abnormalities and further 
evaluate the influence these abnormalities have on subclinical atherosclerosis.  
 
The form and content of this abstract are approved.  I recommend its publication. 
                Approved:  John E. Hokanson 
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1.1. BACKGROUND AND SIGNIFICANCE 
Approximately 84 million individuals in the United States have cardiovascular 
disease (CVD) and it is the leading cause of death averaging one death every forty 
seconds [1]. Obstructive sleep apnea (OSA) is characterized by repeated episodes of 
upper airway collapse during sleep with associated oxygen desaturations and sleep 
fragmentation affecting an estimated 3-7% of adults in the general population [2] and is 
related to incident CVD. The Sleep Heart Health study found that men with severe OSA 
(AHI of >30) had increased risk for incident heart failure and coronary heart disease 
(CHD: heart attack, CHD death, or coronary revascularization procedure) and this risk 
increased by OSA severity [3]. COPD has become the third leading cause of death 
behind CVD and cancer [4] affecting between 10 and 20 million adults [5]. Several 
studies have demonstrated that an obstructive pattern on spirometry is an independent 
risk factor for myocardial infarction, cardiovascular mortality, and stroke [6-9] in 
samples of the general population.  
In 1985, Flenley identified the concurrence of OSA and COPD and devised the 
name Overlap Syndrome (OS) [10] to describe the condition. Today, prevalence has been 
documented to occur anywhere from 1% in population based studies [11, 12] to 40% in 
clinical studies [13] and has been shown to increase the risk for cardiovascular disease 
mortality [13].  
Specifically, atherosclerosis development in OSA and COPD have been 
hypothesized to be caused by inflammatory pathway signaling mediated by hypoxia [12] 
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and subjects with Overlap Syndrome are at greater risk of prolonged oxygen desaturation 
at night than those with OSA alone and degree of airflow obstruction, as measured by 
FEV1/FVC, correlates with risk of prolonged hypoxemia[14]. However, a direct 
relationship between existing oxygenation measures found on a standard polysomnogram 
(desaturation index, baseline SpO2) have shown lack of association with coronary 
calcium measures in adjusted models [15].   
Smoking is a risk factor in both COPD and OSA. In the United States, nearly 47 
million adults smoke cigarettes [16]. Smoking is estimated to cause at least 75% of 
COPD related deaths [17] and smokers with OSA have been found to have a higher AHI 
than nonsmokers [18].  
There have been several studies evaluating the association between OSA and 
COPD. Earlier studies documented a greater prevalence of OSA in COPD and vice versa 
[19, 11] however these studies were limited to small clinic samples and possible selection 
bias. Later, larger population based studies showed no association between OSA and 
COPD [20, 21] however; these were limited by evaluating OSA in mild COPD.  
Two pulmonary abnormalities included in the definition of COPD are chronic 
bronchitis and emphysema. In 2011, over ten million Americans reported a physician 
diagnosis of chronic bronchitis [22].  Chronic bronchitis is chronic inflammation of the 
bronchi (medium-size airways) in the lungs. It is defined clinically as a persistent cough 
that produces sputum (phlegm) and mucus, for at least three months per year in two 
consecutive years [22].  Chronic bronchitis is caused by recurring injury or irritation to 
the respiratory epithelium of the bronchi, resulting in chronic inflammation, swelling, and 
thickened fibrotic bronchial walls with luminal narrowing. 
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Increased numbers of mucus-producing cells in the bronchi and bronchioles and 
enlargement of the tracheal mucus glands results in an increased secretion of mucus.  
Airflow resistance characteristic of chronic bronchitis is primarily due to goblet cell 
metaplasia creating mucus plugs in the bronchioles with concurrent bronchiolar fibrosis 
and inflammation. Cells involved with mucus production; IL 13 and IL 4[23] levels have 
been found to be greater in subjects with chronic bronchitis [24] and are greater in the 
central airways of smoking subjects with chronic bronchitis compared to asymptomatic 
smokers [24]. 
The other form of COPD; emphysema is a long-term, progressive obstructive lung 
disease in which the alveoli that promote oxygen exchange between the air and the 
bloodstream are destroyed causing increased shortness of breath and a loss of elasticity in 
the alveolar walls. In 2011, 4.7 million Americans reported ever bring diagnosed with 
emphysema [22]. 
Although chronic bronchitis and emphysema are included in the definition, COPD 
is typically defined by pulmonary function measurements. This is a serious limitation as 
COPD is a heterogeneous disease whose clinical, functional, and radiological 
presentation varies from patient to patient despite similar degree of airflow limitation 
[25-28]. COPD can encompass emphysema and chronic bronchitis independently or in 
conjunction and may or may not be accompanied by declines in pulmonary function.  
Magee et al, found that TLC%, FRC%, and RV% were increased in smoking 
subjects with mild to moderate and severe emphysema compared to life time non-
smoking controls and there were decreases in FEV1pp, and FEV1/FVC in the same group 
of subjects [29] whereas the ECLIPSE study found no difference in FEV1pp and 
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FEV1/FVC in subjects with chronic bronchitis compared to subjects without chronic 
bronchitis irrespective of GOLD stage [28]. Alonso and colleagues specifically compared 
pulmonary function measures between subjects with emphysema and chronic bronchitis 
and found that emphysema subjects had lower FEV1 values and greater levels of dyspnea 
compared to bronchitis subjects [30]. 
A recent study found a higher prevalence of OSA in subjects with chronic 
bronchitis [31, 30] and increase in cardiovascular risk factors [30] however data was 
limited thus it is important to fully evaluate the relationship between OSA and COPD by 
evaluating the individual pulmonary abnormalities to fully understand the complexities of 
this relationship and involvement in CVD development.  
This will be the first study to examine the relationship between OSA and different 
pulmonary abnormalities and further determine the effects these abnormalities have on 
the relationship between OSA and subclinical atherosclerosis. In addition, we will 
evaluate differences in oxygen re-saturation by varying groups with Overlap Syndrome.  
1.2. SPECIFIC AIMS AND HYPOTHESES  
The proposed study is structured as an ancillary study to the Genetic Determinants 
of COPD Study (COPDGene) funded by NIH-NHLBI.  The proposed ancillary study has 
been reviewed and approved by the COPDGene Executive Committee and National 
Jewish Health IRB protocol number HS 2738. The is a well characterized cohort of 
Caucasians and African Americans, with pulmonary function measures, standardized 
questionnaires and chest computed tomography scans capturing a wide spectrum of 
pulmonary abnormalities with and without overlap between diseases. Through this work, 
we expect to gain a better understanding of Overlap Syndrome; specifically understand 
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the relationship between OSA and varying pulmonary abnormalities (reduced pulmonary 
function, chronic bronchitis, emphysema) and evaluate the impact each abnormality has 
on the relationship between OSA and subclinical atherosclerosis in our study sample, 
examine if there is a difference in re-saturation time between Overlap Syndrome groups, 
and lastly evaluate the validity of self-reported OSA in a single site convenience sample 
from the COPDGene cohort.    
The overall goal of the proposed research is to explore the pathway between OSA 
and subclinical atherosclerosis with measures of calcification from coronary and thoracic 
arteries and determine if these relationships are altered by pulmonary abnormalities. 
Additionally, we will assess the validity of self-reported OSA and the utility of the Berlin 
sleep questionnaire in a pulmonary population. We propose the following specific aims 
and hypotheses: 
1.2.1. Specific Aim 1  
The first specific aim is to examine the relationship between Obstructive Sleep 
Apnea and pulmonary abnormalities.  We will examine whether diagnosis of OSA as 
measured by a.) Self-report, b.) Polysomnograhy are associated with pulmonary 
abnormalities as measured by pulmonary function, chest computed tomography scan, and 
series of self-reported questions in a smoking population.  
We hypothesize subjects with OSA will have reduced pulmonary function, 
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1.2.2. Specific Aim 2 
The second specific aim is to examine the relationship between Obstructive Sleep 
Apnea and coronary/thoracic calcium measures and determine whether varying 
pulmonary abnormalities alter these relationships. We will examine whether diagnosis of 
OSA as measured by a.) Self-report, b.) Polysomnography are associated with coronary 
and thoracic calcium measures as quantified by chest CT and further assess whether 
presence of pulmonary abnormalities changes these relationships.   
We hypothesize that subjects with OSA will have increased atherosclerosis-
related aberrations and these relationships will differ by presence of pulmonary 
abnormalities. 
1.2.3. Specific Aim 3   
The third specific aim is to evaluate oxygen re-saturation in subjects with Overlap 
Syndrome. We will examine whether re-saturation as assessed by the time interval from 
peak de-saturation to return to baseline on the SpO2 channel of the polysomnogram is 
different in subjects with OSA alone versus categories of Overlap Syndrome. 
We hypothesize that subjects with OSA will have faster re-saturation time 













Smoking is a risk factor in both COPD and OSA. In the United States, nearly 47 
million adults smoke cigarettes [16] and smoking is estimated to cause at least 75% of 
COPD related deaths [17]. 
 Smoking has been implicated in OSA. It has been reported that smokers have a 
higher apnea/hypopnea index (AHI) than nonsmokers [18]. Results from the Wisconsin 
Sleep Cohort found that in 811 adults, an AHI of at least 5 per hour was three times more 
likely in current smokers than never smokers and individuals who smoked ≥40 cigarettes 
per day (heavy smokers) had 6.74 times greater odds of having an AHI of at least 5 [32]. 
In another study done by Hoffstein, [33] it was found that there was a greater number of 
current smokers and pack-years among individuals with an AHI ≥50 than among those 
with an AHI of <10.  
2.2. HYPOXIA 
OSA is characterized by recurrent nocturnal obstruction of the upper airway. Each 
episode of airway obstruction is usually followed by a marked decrease of arterial oxygen 
saturation, which rapidly normalizes after ventilation resumes. This intermittent hypoxia 
can occur hundreds of times a night in severe OSA cases.  
Two contributors to hypoxemia in COPD patients are alveolar hypoventilation 
and ventilation/perfusion mismatching.  Becker and colleagues measured minute 
ventilation in normal subjects and subjects with COPD and found little change in normal 
subjects transitioning from a wake state to non REM sleep and REM sleep whereas 
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COPD subjects had a dramatic decrease in minute ventilation during the same transition 
periods (16% from wake state to non–REM sleep and 32% from non-REM sleep to REM 
sleep, respectively) largely as a result of reduction in tidal volume [34].  
In emphysema, ventilation/perfusion (V/Q) mismatch results from airflow 
limitation and destruction of the pulmonary capillary bed [35]. COPD patients with 
predominantly emphysema subtype have increased ventilation of poorly perfused lung 
units (ie, high V/Q ratio) [36] conversely, subjects with a significant degree of airway 
disease (bronchitis) are more likely to have a low V/Q ratio, with heterogeneous alveolar 
hypoventilation: perfusion of under-ventilated areas.  
Hypoxic induced inflammation has been identified as an important pathway in 
which CVD develops from both OSA and COPD although different pathways have been 
implicated. In an in vitro model, Ryan and colleagues found a preferential activation of 
NF-kB during intermittent hypoxia as occurs in OSA versus HIF-1 activation during 
sustained hypoxia as occurs in COPD [37] and Feng et al found that there is a selective 
and dose dependent activation of inflammatory pathways (NF-kB) from intermittent  over 
chronic hypoxia [38] and it was also found that the ensuing inflammatory damage from 
hypoxia is from the re-oxygenation phase rather than the de-saturation phase [39] as 
indicated by increase in inflammatory markers. It has been postulated that intermittent 
hypoxia is analogous to ischemia-reperfusion injury where damage occurs when blood 
flow to a hypoxic tissue is restored indicated by the production of reactive oxygen species 
(ROS) [40-42] which has been shown to be augmented in OSA [43].  
Subsequently, inflammatory markers are increased in both OSA and COPD. 
Circulating levels of leukocytes, platelets, fibrinogen, and C-reactive protein (CRP) have 
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been found to be higher in those with airflow obstruction compared to those without [44]. 
In addition, it has been shown that patients with OSA present with certain systemic 
inflammatory markers such as TNF-α [45], interleukin-6 [45], leptin [46,47], adhesion 
molecules [48], and markers of oxidative stress [49,43]. Prior research has shown that the 
inflammatory levels are decreased after treatment with continuous positive airway 
pressure (CPAP) which is the main treatment for OSA. CPAP at 6 months has been 
shown to markedly decrease CRP levels in men and women with moderate to severe 
OSA [50-55] as well as decrease levels of IL-6 [55]. In addition, Steiropoulos and 
colleagues found that men who used CPAP for ≥4 hours a night, were able to 
significantly decrease TNF-α levels [52].  
Both COPD and OSA are associated with elevated levels of C-reactive protein 
(CRP) and IL-6, in addition to tumor necrosis factor (TNF)-a and IL-8 [44-48], and are 
also associated with oxidative stress [49,43] although factors such as obesity and 
smoking confound this relationship. Hypoxia has been implicated as an important 
pathway in which CVD develops from both OSA and COPD although there are different 
hypoxic origins for both conditions. Hypoxia induces NF-kB and HIF-1 activation which 
regulates genes that promote tissue perfusion and oxygenation [56].  
In an in vitro model, Ryan and colleagues found a preferential activation of NF-kB 
during intermittent hypoxia versus HIF-1 activation during sustained hypoxia [37]. All 
inflammatory pathways have been implicated in endothelial dysfunction and subsequent 
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Figure 2.1. Overlapping Mechanisms of Systemic Inflammation in COPD and OSA 
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2.3. OXYGEN DISSOCIATION CURVE 
Hypoxia has important implications for understanding how blood carries and 
releases oxygen in the body. This is represented by the Oxygen Dissociation Curve 
(ODC, Figure 2.2.) the plot between Hemoglobin (Hb) oxygen saturation and the partial 
pressure of oxygen in blood. The position of the ODC is arbitrarily determined by the 
partial pressure of oxygen in blood associated to a Hb oxygen saturation of 50% (P50). 
The P50 helps to diagnose a right (reduced affinity- increased O2 release) or a left shift 
(increased affinity-decreased O2 release) of the ODC.  
A partial pressure of Oxygen (PO2) of around 60mmHG, corresponds to an 
oxyhemoglobin saturation of around 90% with subsequent increase in PO2 not 
significantly impacting the affinity of oxygen to hemoglobin. For example, a rise from 60 
mmHg to 80mm Hg (normal PaO2, 80-100mmHg) only corresponding to approximately a 
5% increase in saturation whereas reductions of PO2 below 60 mmHg correlate to a sharp 
drop in oxygen saturation. At high partial pressures (lungs) there is an increased affinity 
to hemoglobin while reduced affinity occurs closer to the body tissues [58, 57].   
Three factors can cause a right shift of the ODC thus reducing the loading of oxygen in 
the lungs and enhance release of oxygen to the tissues yielding a lower oxygen saturation 
(SaO2) for any given PO2. One factor, 2, 3 diphosphoglycerate (2, 3-DPG) blood 
concentration influences the ODC under the effect of hypoxia. A study in OSA subjects 
found that intermittent hypoxia at night alone is not enough to increase levels of 2, 3 
DPG [59] and move the oxygen dissociation curve to the right as happens in subjects 
with daytime hypoxemia [60]. Elevated levels of 2, 3-DPG have been documented in  
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healthy subjects submitted to hypobaric hypoxia [61, 60], patients with chronic anemia 
[62], and heart failure [63]. 
 
Figure 2.2. Oxygen Dissociation Curve.  
Figure adapted from Julian Gomez-Cambronero [57]. The solid line represents a normal 
curve. The orange square represents a hemoglobin molecule with four iron based  
heme units inside the box of which oxygen molecules bind and four globin subunits outside of the box. 
 
Another factor favoring a right shift in the ODC is decrease in pH. Decrease in pH 
can be the result of hypoventilation from a diffusion defect [64], decreased functional 
residual capacity (FRC), or ventilation/perfusion mismatching in COPD [35, 36]. 
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2.4. HYPOXIC VASOCONSTRICTION  
Hypoxic pulmonary vasoconstriction is intrinsic to the lungs and is an adaptive 
motor response to alveolar hypoxia in an attempt to oxygenate body tissues by 
redistributing blood to optimally ventilated lung segments. This process occurs within 
seconds to minutes [65, 66] of the hypoxic stimulus. Due to their elastic and recoil 
properties the largest proximal arteries act as conduit vessels with a biphasic response to 
hypoxia with an initial constriction followed by sustained relaxation [67] whereas the 
smaller muscularized arteries act as resistance vessels and constrict in response to 
hypoxia [65,68-69] and remain constricted as long as the hypoxic stimulus persists. 
Hypoxia triggers cell proliferation of the endothelial cells, medial smooth muscle 
cells, and adventitial fibroblasts of the pulmonary vasculature within 24 hours [70] and if 
prolonged, leads to pulmonary vascular remodeling which has been exhibited in smokers 
[71-72].  
Endothelial dysfunction is an early marker of vascular abnormality preceding 
CVD and is marked by a selective up regulation of Endothelin-1 (ET-1) in the lungs in 
response to hypoxia. ET-1, a potent vasoconstrictor increases during several hours of 
untreated OSA [75] and is reduced with CPAP treatment [76]. Endothelium dependent 
vasodilators are reduced in healthy patients with severe OSA compared to age and BMI 
matched controls [77-78] Hypoxia has been implicated as the most important mechanism 
leading to pulmonary vasoconstriction and pulmonary hypertension [79] leading to 
cardiovascular disease by raising pulmonary pressures, causing right ventricular 
hypertrophy and ultimately Cor pulmonale. Matsuoka and colleagues found that the cross 
sectional area in pulmonary vessels <5mm2diameter was related to an increase in mean 
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pulmonary arterial pressure [79]. In rat models, the development of pulmonary artery 
hypertension and subsequent right ventricular hypertrophy from hypoxia resulted in an 
increase in right ventricular membrane–bound ACE activity [80] and in animals with 
chronic hypoxia, treatment with ACE inhibitors reduced right ventricular hypertrophy 
and fibrosis [81]. 
Pulmonary vascular remodeling in COPD has been shown to be related to both 
IL-13 [82] and IL-18 [83] expression with as early as 2 days of hypoxia, an up regulation 
of cytokines IL-13 and IL-4 [84]. IL-18 activation can cause complex alterations in the 
lung including emphysema, airway and vascular remodeling and is strongly expressed in 
both the bronchiolar and alveolar epithelium in patients with very severe COPD (GOLD 
stage IV) [85]. Specifically, in emphysema, the parenchymal response is mediated by 
IFN-γ while the vascular and airway responses in COPD are mediated by IL-13 [86]. IL-
13 has been shown to have an inverse association with % FEV1 and DLCO [87].  
In COPD patients, expression of IL-18 correlate negatively with pulmonary 
function (FEV1% predicted) [88, 89] but not FEV1/FVC ratio and serum levels of IL-18 
increase by COPD severity as indicated by GOLD stage [83]. IL-18 is important as it is a 
pro-inflammatory cytokine that induces the production of TNFα [90], which in turn 
promotes the synthesis of IL-6 [91], and IL-6 regulates the synthesis of CRP in the liver 
[92] which are all increased in COPD and OSA [44-45] Like IL-6 and CRP, IL-18 is 
considered a strong marker for cardiovascular mortality [92]. 
2.5. CORONARY AND THORACIC ARTERIAL CALCIFICATION 
In OSA, repetitive hypoxia/re-oxygenation associated with apneas and hypopneas 
up-regulates the production of inflammatory mediators and expression of adhesion 
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molecules [93-96]. The accumulation and adhesion of circulating leukocytes to the 
vascular endothelium lead to vessel inflammation and progression of atherosclerosis [97-
98]. In COPD, recognized biological mechanisms precluding CVD involve direct effects 
of tobacco on the cardio-respiratory system and are mediated through oxidative stress and 
inflammation. This leads to endothelial dysfunction, enhanced platelet aggregation, 
oxidation of LDL-cholesterol, plaque accumulation and ultimately plaque rupture [99]. 
Coronary artery calcium (CAC) is a marker of subclinical atherosclerosis and can be 
detected on low dose, nongated computed tomography scans simultaneously with 
Thoracic arterial calcium (TAC). CAC has been shown to have a strong association with 
risk of future coronary heart disease (CHD) events and mortality [99–106] as well as 
asymptomatic myocardial ischemia [106-108].  
TAC has been shown to be associated with coronary risk factors [109] and 
correlates with CAC [110]. A recent study has shown that CAC and TAC may be 
beneficial in predicting different vascular events. Jacobs et al, showed that in a high risk 
population of smokers CAC was a stronger predictor of CVD events whereas TAC was a 
stronger predictor of non-CVD events (e.g., stroke) [111]. CAC has been modestly 
studied in COPD and OSA with conflicting results. Sorajja et al, examined CAC in 
subjects with no history of coronary disease and found that CAC was increased in OSA 
subjects and CAC significantly increased with OSA severity adjusted for demographics 
and coronary risk factors [112]. Another study by Kepez and colleagues resulted in a lack 
of independent association between OSA and OSA severity and coronary calcium scores 
however, there were limitations to this study: small sample size (n=110) [113].  
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In evaluating the relationship between COPD and CAC, a study from Newman 
and colleagues found that history of COPD was related to highest quartile of CAC 
independent of age, gender, smoking exposure, and triglycerides [114] however the Mesa 
study found that obstructive airflow was significantly related to internal media thickness 
of the internal carotid artery and common carotid artery but not significantly related to 
CAC [115]. Other studies have attempted to evaluate different pulmonary manifestations 
of COPD and relationship with CAC; specifically emphysema and FEV1 decline. Studies 
have found that there is more CT emphysema in subjects with CAC however, the 
independent relationship between emphysema and CAC [115-116] lacked significance 
while another study found a significant relationship between FEV1 reduction and CAC 
[117].  Nonetheless these studies did not account for the overlap between OSA and 
various pulmonary abnormalities. To date, there are no studies having looked at the 
impact of both OSA and pulmonary disease on coronary and thoracic calcium measures. 
2.6. ROLE OF OTHER COVARIATES 
 Many of the risk factors for plaque formation are similar in OSA and COPD. Age 
and gender are the most important risk factors for coronary calcification, ranging from 
14% for men and women less than 40, to 93% to 100% for men older than 70, and 77% 
to 100% for women older than 70 [118-122]. Several investigators have studied risk 
factors for their association with coronary artery calcifications. Elevated plasma 
cholesterol has most consistently been shown to be associated with coronary calcification 
[123-128]. Additional risk factors for coronary calcification consist of age, [125] 
cigarette smoking, [124-125,127] elevated blood pressure, [125,127] obesity [127], and 
diabetes [128].  
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In OSA, shared risk factors with coronary calcium include advanced age, male 
sex, and obesity although the underlying mechanisms remain unclear. It has been 
proposed that the pathways linking these risk factors for OSA can be explained by 
anatomical abnormalities such as decreased cross sectional area of the upper airway as 
assessed by CT scan and MRI [129-131] increasing the propensity of airway collapse in 
sleep.  
Mechanism of greater OSA as one gets older include an increased deposition of 
fat in the pharyngeal area, lengthening of the soft palate, and changes in body structures 
surrounding the pharynx [132]. OSA tends to be more prevalent in men than in women. It 
is unclear exactly why this is the case although it can be attributed to anatomical and 
functional properties of the upper airway and in ventilatory response to arousals from 
sleep [133]. Imaging studies have revealed that men have increased fat deposition around 
the pharyngeal airway as compared to women [134]. Although OSA is more prevalent in 
men compared to women some studies hypothesize a role of menopause in OSA as 
studies have shown that OSA is more common among postmenopausal than among 
premenopausal women [135-137] The transition to the postmenopausal period and 
associated hormonal changes may increase the risk of developing OSA but this 
hypothesis is debated [138-139]. The Sleep Heart Health study found that use of estrogen 
only or estrogen and progesterone decreased the odds of an AHI  of ≥15 by 40-50% for 
all age groups (50-59, 60-69, and 70-79) [140]. In addition, several studies have shown 
CRP to be greater in women compared to men [141-143] although CRP levels increase to 
a greater degree with increasing adiposity in women [144]. It has also been documented 
that inflammatory markers take a longer time to return to normal in women treated with 
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CPAP compared to men. Mermigkis et al found that although CRP levels decreased for 
both males and females at 6 months post CPAP treatment, at 3 months women had a very 
small, insignificant reduction in CRP levels as compared to men who had a significant 
decrease in CRP levels [144]. Studies have shown that African Americans have a greater 
prevalence of OSA compared to whites [145-147].  
The link between OSA and obesity has been clearly documented with weight 
change impacting the Apnea-Hypopnea Index (AHI), a measure of OSA severity. The 
Wisconsin Sleep Cohort Study, found that 10% weight gain predicted a 32% increase in 
AHI score; conversely a 10% weight loss predicted a 26% decrease in AHI score over a 
4-year period [148]. The relationship between OSA and obesity was replicated in the 
Sleep Heart Health Study and Cleveland Family Study [149-150]. Obesity/visceral 
obesity is a  risk factor  for the development of OSA and thought to be associated with 
anatomic alterations that predispose to upper airway collapsibility during sleep by 
increasing adiposity around the pharynx and body. Central obesity has been associated 
with a reduction in lung volume which leads to a loss of caudal tracheal traction on the 
upper airway hence, an increase in pharyngeal collapsibility [150].  
An increased prevalence of OSA in subjects with type II diabetes has been shown 
in multiple studies [151-153] and this association appears to be independent of obesity 
[154-156]. A study of men referred for assessment of sleep showed those with OSA were 
significantly more likely to have impaired glucose tolerance (IGT) and diabetes than were 
those without OSA [154]. The Sleep Heart Health Study showed a significant association 
between oxygen de-saturation during sleep and elevated fasting and 2-h plasma glucose 
concentrations [156].  
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Because hypoxia is an important pathway to the development of plaque formation 
in both OSA and COPD, it is important to consider and possibly control for medications 
in which subjects with COPD are commonly treated. Studies have shown that treatment 
of the underlying obstructive lung disease is helpful in preventing or reducing nocturnal 
oxygen de-saturation in those with COPD [157-158]. Marin and colleagues studied the 
effects of daily ipratropium use in subjects with moderate to severe COPD and found that 
after 4 weeks of four times daily use, nocturnal oxygen saturation improved [159]. Data 
also exists for the use of oral steroids and improvement of nocturnal oxygen saturation in 
COPD [160]. 
2.7. INNOVATION 
Although studies have looked at the relationship between OSA and COPD as 
measured by both GOLD stage and FEV1pp/FVC, there are no studies that have 
attempted to further dissect the underlying pathophysiologic relationship between OSA 
and COPD looking at the relationship between OSA and pulmonary abnormalities 
(chronic bronchitis, emphysema) as assessed by mechanisms other than pulmonary 
function: questionnaire and chest CT scan. Our preliminary analysis (Section 2.8) showed 
that there is an interaction between OSA and COPD on CVD however, this was not a 
result of pulmonary function and this relationship differed by distinct CVD outcomes 
which warrants further exploration of this interaction examining the relationships of OSA 
with chronic bronchitis and emphysema separately.  
Secondly, no studies have examined the interactive effect between OSA, 
pulmonary abnormalities and subclinical atherosclerotic measures. Two previous studies 
showed conflicting results in the relationship between OSA and coronary artery calcium 
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measures; one showing a positive association between OSA and OSA severity and CAC 
[112] and the other study showing no independent association between OSA and OSA 
severity and CAC measures [113]. 
To date, there are no studies evaluating the relationship of OSA with thoracic 
calcium. This is important as CAC and TAC could serve as proxies for different CVD 
outcomes [111]. Studies have shown that OSA is related to various CVD conditions; 
some of which are mediated through an atherosclerotic process (CAD, heart attack, and 
angioplasty) [3] while others are not (heart failure, peripheral vascular disease) [3] 
however, the impact of OSA and subclinical CVD measures and whether pulmonary 
abnormalities alter these relationships have not been studied. In addition, on a subset of 
COPDGene subjects we will be examining the influence of OSA severity as measured by 
AHI through polysomnography on the relationship with pulmonary abnormalities and 
subclinical CVD (CAC and TAC).  
Lastly, in a convenience sample of subjects with available sleep study records, we 
will create a new re-saturation variable to assess if re-saturation time varies within a 
subject and further determine if re-saturation time differs by Overlap Syndrome groups. 
Presence of specific pulmonary manifestations and accompanying hypoxia may exhume 
differing effects on the development of subclinical CVD. These are extremely important 
considerations when examining these associations as CVD is the leading cause of death 
[1] and understanding the pathways by which subclinical CVD could develop will assist 
physicians with understanding the importance of evaluating OSA within their COPD 
patients and assist with tailoring treatments/tests dependent on the pulmonary 
abnormality identified. 
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2.8. PRELIMINARY DATA 
In preliminary analysis, we found that Overlap Syndrome increased the risk of 
aggregate CVD and specifically had the greatest association with Congestive Heart 
Failure (CHF) followed by Coronary Arterial Bypass Graft (CABG), Heart Attack, and 
Peripheral Vascular Disease (PVD) [161]. Presence of OSA seemed to have a greater 
impact on CVD than COPD as defined by pulmonary function. Within COPD, subjects 
with OSA had a 32% increased risk of CVD (OR=1.32, 95%CI= 1.06-1.63, p<0.001) 
however within OSA, presence of COPD increased the risk of CVD by 17% (OR=1.17, 
95% CI=1.07-1.86, p<0.05) [161].  
In addition, there was a statistically significant interaction between all COPD 
(measured by GOLD stages 1-4) and OSA on the relationship with aggregate CVD and 
this relationship differed by distinct CVD outcomes suggesting not only an interaction 
between OSA and COPD but differential pathways by which OSA and COPD may 
influence distinct CVD outcomes (Figure 2.3).  
Both OSA and COPD were independently related to atherosclerotic CVD 
processes (CAD variable) and cerebrovascular disease (Stroke variable) however, having 
both conditions were only significantly related to CAD and CHF. The occurrence of both 
conditions had an additive effect on CHF. Interestingly, in the same analysis omitting 
GOLD stage 1 subjects, who resembled smoking controls in terms of FEV1% predicted, 
showed similar associations for all outcomes with exception to CAD. As hypothesized, 
having Overlap Syndrome had an additive effect on the CAD outcome.  
After further exploration, it was found that this interaction was not a result of 
pulmonary function as defined by GOLD stage (OSA*GOLD stage; p=0.12) lending the  
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Figure 2.3. Relationship between OSA, COPD, Overlap Syndrome with Distinct CVD 
Outcomes * Indicates statistical significance p<0.05; CAD= Coronary Artery Disease (CAD), 
Coronary Arterial Bypass Graft (CABG), Angioplasty, and Heart Attack; Stroke= Stroke and 
Transient Ischemic attack (TIA); CHF=Congestive Heart Failure; PVD=Peripheral Vascular 
Disease; all comparisons against subjects having neither OSA nor COPD.  
 
thought of pulmonary function in defining COPD as a poor measure for evaluating the 
interaction between OSA and COPD and further assessment is needed in evaluating 
Overlap Syndrome and the effect on CVD. Taking in consideration the heterogeneity of 
COPD, we looked at the presence of self-reported chronic bronchitis and chest CT 
emphysema by GOLD stage (Figure 2.4.) in the COPDGene cohort.  
Although prevalent emphysema and chronic bronchitis increase with COPD 
severity (Jonckheere’s Terpstra test for trend, p<0.0001, for emphysema and chronic 
bronchitis, respectively), it is important to note that chronic bronchitis and emphysema 
occur in subjects across the range of functional limitation.  
Within COPDGene, 18% of all participants have only chronic bronchitis (n=1282) and 
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Figure 2.4. Proportion of Prevalent Emphysema and Chronic Bronchitis by GOLD stage in 
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CHAPTER III 
RESEARCH DESIGN AND METHODS 
3.1. STUDY POPULATIONS 
COPDgene is a multicenter epidemiologic case-control study of 10,192 current 
and former smoking men and women, non-Hispanic White and African American 
between the ages of 45 and 80, with at least a 10 pack year history of smoking. The study 
was designed to study the genetic susceptibility to COPD. Subjects were recruited based 
on presence or absence of COPD as defined by post bronchodilator spirometry 
measurements (forced vital capacity; FVC < 0.70) and further characterized by severity 
using forced expiratory volume in one second percent predicted (FEV1pp) as defined by 
the Global Initiative for Obstructive Lung Disease (GOLD stage) criteria [162].  
Subjects were recruited from twenty one clinical centers throughout the United 
States. Local IRB approval was obtained by each clinical site to enroll subjects, and all 
subjects gave written informed consent prior to participation in the study. Additional 
details of the study design and baseline recruitment have been published [163].  The 
COPDGene study is currently funded for another 5-year period (07/13 – 07/18/17).  A 
follow-up study visit will be conducted approximately five years after the baseline visit.   
A single site sample of COPDGene subjects from National Jewish Health were 
recruited for the ancillary study collecting additional sleep data from the Berlin Sleep 
questionnaire and existing polysomnographic recordings. Approval was obtained from 
the National Jewish Health Institutional Review Board and COPDGene executive 
committee to conduct the ancillary study. Nine hundred and eighty-three COPDGene 
participants from National Jewish Health had given the parent COPDGene study 
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permission to be re-contacted for additional studies. A clinical sample (n=406) of 
National Jewish Health participants were verified as having a positive diagnosis of OSA 
or lack thereof with 98 of the subjects having previously conducted polysomnographic 
data recorded in the National Jewish Health electronic medical record database. 
3.2. AVAILABLE COPDGENE DATA 
This section briefly describes the data collection that has already been completed 
and data that are available for analysis in the proposed study. 
3.2.1. Obstructive Sleep Apnea 
Self-reported OSA will be identified in the full COPDGene cohort using 
questions from the medical history questionnaire: Have you ever been told you have 
sleep apnea and/or have you ever been told by a physician that you have sleep apnea?   
3.2.2. Pulmonary Abnormalities 
CT scans were acquired using multi-detector CT scanners (at least 16 detector 
channels). Volumetric CT acquisitions were obtained both on full inspiration (200 mAs), 
and at the end of normal expiration (50 mAs) [163]. Image reconstruction utilized sub-
millimeter slice thickness, with smooth and edge-enhancing algorithms. The following 
analyses were performed on segmented lung images, using Slicer (www.Slicer.org): total 
inspiratory and expiratory lung volumes, and relative lung volumes falling below 
attenuation thresholds of −950, −910 and −856 HU. Measures of emphysema were 
reported using the -950HU threshold (%LAA-950) from the inspiratory scans and 
measures of gas trapping were reported using -856HU threshold (%LAA-856) on 
expiratory scans. Subjects with the emphysema type met a threshold value of ≥5 percent 
emphysema of the total lung from chest CT scans. These thresholds were 
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determined based on work from Zach and colleagues evaluating CT thresholds in non-
smoking controls [164]. The chronic bronchitis type was defined by standard protocol as 
chronic productive cough for 3 months in each of 2 successive years in a patient of whom 
other causes of productive chronic cough have been excluded [165]. Functional reduction 
was defined by spirometry measures. Pre and post bronchodilator spirometry values were 
obtained from each subject using the ndd EasyOneTM spirometer (Zurich, Switzerland) 
using standard protocol [166]. Post-bronchodilator measurements were taken 15-20 
minutes after the administration of 2 puffs of Albuterol with use of Aerochamber and 
nose clips.  
Airflow obstruction was defined as an FEV1/FVC ratio of <0.70. Subjects were 
further classified by severity as follows: GOLD stage 0; FEV1 ≥0.80 predicted and 
FEV1/FVC ≥0.70, GOLD stage 1; FEV1 ≥80% predicted and FEV1/FVC <0.70, GOLD 
stage 2; 50% ≤ FEV1< 80% predicted and FEV1/FVC <0.70, GOLD stage 3; 30% ≤ 
FEV1<50% predicted and FEV1/FVC<0.70, and GOLD stage 4; FEV1 <30% predicted 
and FEV1/FVC <0.70. COPDgene also has a unique group of subjects that do not fit into 
the classic definition of cases or controls; GOLD stage U with FEV1< 0.80% predicted 
and FEV1/FVC ≥ 0.70.  
In defining the pulmonary abnormality category by function, cases were defined 
as GOLD stages 2-4 and controls were defined as subjects without chronic bronchitis, no 
emphysema, and normal pulmonary function (GOLD stage 0). Prior research has shown 
associations between FEV1pp and inflammatory markers significant to 
CVD/Atherosclerosis [83, 88-89] development thus it was important not to exclude 
subjects with reductions of FEV1pp (GOLD undefined). 
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3.2.3. Calcification Measures 
Images were obtained at 2.5 mm intervals beginning one centimeter below the 
carina and progressing caudally to include all coronary arteries. Ungated thoracic images 
were obtained in the helical mode, with a pitch of 1.375. The settings of the GE 64 
scanner (Light Speed VCT, General Electric Medical System, Milwaukee, WI) were 120 
kVp, 430 mA, 500 ms/per rotation. Effective radiation dose using this technique was 
approximately 1 mSv per patient, measured effective dose (ED) was calculated by 
multiplying the dose length product by the conversion factor for the chest (0.014). 
 Images were reconstructed as contiguous 2.5 mm slice thickness for measures of 
Coronary arterial calcium (CAC) and Thoracic arterial Calcium (TAC). TAC was defined 
as either ascending or descending thoracic aortic calcium, as present from the pulmonary 
artery bifurcation superiorly to the cardiac apex inferiorly. The TAC of the ungated 
reconstructed images were measured using the same range as the gated scan, to allow 
more direct comparison of the measures.  
Both coronary and thoracic aortic calcium were classified using a CT threshold of 
130 Hounsfield units (HU) involving 3 contiguous voxels for identification of a calcific 
lesion resulting in a minimum lesion area of 1.02 mm2. The lesion score was calculated 
using the area density method, by multiplying the lesion area by a density factor derived 
from the maximal HU within the area as described by Agatston [167]. The density factor 
was assigned in the following manner: 1 for lesions whose maximal density was 130–199 
HU, 2 for lesions 200–299 HU, 3 for lesions 300–399 HU, and 4 for lesions >400 HU. A 
total CAC score was determined by summing individual lesion scores from each of four 
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anatomic sites (left main, left anterior descending, circumflex, and right coronary 
arteries). 
3.2.4. Smoking, Demographics, Medications and Other Covariates 
Smoking status was a created variable of current and former smokers using a 
modified questionnaire taken from the ATS adult respiratory questionnaire [168]. 
Subjects were classified as current smokers if they answered “Yes” to the following 
question: Do you now smoke cigarettes (as of a month ago)? Subjects who did not 
answer “Yes” to the aforementioned question were classified as former smokers. 
Pack-years were calculated using standard questions from the ATS Adult 
Respiratory Questionnaire. The average number of cigarettes smoked per day was 
divided by twenty to convert to packs.    
Treatment for OSA was collected by self-report as being treated with a positive 
airway pressure device; continuous positive airway pressure (CPAP) or bi-level positive 
airway pressure (BiPAP) device.   
Age, gender, and race were ascertained from a demographic questionnaire. Body 
mass index was calculated by dividing weight in kilograms by meters squared (kg/m2). A 
medication questionnaire was used to identify all medications (brand name and generic) 
taken by each subject and designated by an open field in a medication specific dataset. 
We used a SAS macro to pull in all possible medications then merged the medication 
dataset with the main COPDGene dataset further defining medication categories and 
covariates accordingly. Covariates such as high blood pressure and high cholesterol 
were defined by self-report as many medications which could have assisted with defining 
the covariates were important to adjust for in multivariable models given specific 
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hypotheses. Diabetes was defined by self-reported diabetes and/or use of at least one of 
the listed diabetic medications: 1.) Insulin; Insulin, Apidra, Glulisine, Humalog, Novolog, 
Humulin, Novolin, Lantus, Levemir, 2.) Oral medications: Glimepiride, Amaryl, 
Glipizide, Glucotrol, Glyburide, Diabeta, Micronase, Acarbose, precise, Miglitol, Glyset, 
Linagliptin, Tradjenta, Saxagliptin, Onglyza, Sitagliptin, Januvia, Metformin, 
Glucophage, Exenatide Byetta, Liraglutide, Victoza, Nateglinide, Starlix, Repaglinide, 
Prandin, Pioglitazone, Actos, Rosiglitazone, Avandia, Bromocriptine, Cycloset, 
Colesevelam, Welchol, Pramlintide, Symlin.   
3.3. COPDGENE DATA TO BE COLLECTED  
This section describes new data collection that will be conducted for the proposed 
study. 
3.3.1. High Risk Obstructive Sleep Apnea 
In a single site sample of (n=1371) COPDGene participants (n=983) from 
National Jewish Health agreed to participate, and were sent the Berlin Sleep 
Questionnaire. The Berlin Sleep questionnaire has been shown to have a 0.86 sensitivity, 
0.77 specificity, and a positive predictive value of 0.89 in identifying high risk subjects 
(RDI>5) with OSA [169] in a general clinic population.  
The determination of high and low risk sleep apnea was based on the 
questionnaire responses in three symptom categories. For category 1, a positive response 
was defined as persistent symptoms (3 to 4 times/wk.) in two or more questions about 
their snoring. For category 2, a positive response was defined as persistent (3 to 4 
times/wk.) wake time sleepiness, drowsy driving, or both. For category 3, a positive 
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response was defined as a history of high blood pressure or a body mass index more than 
30 kg/m2.  
To be considered at high risk for obstructive sleep apnea, a patient had to qualify 
as indicated by a positive score: ≥2 in at least two symptom categories. Subjects denying 
persistent symptoms or only qualifying in one symptom category: positive score <2 were 
considered low risk. A copy of the Berlin Sleep questionnaire is included (Appendix A).  
The Berlin sleep questionnaire data in addition to data from self-reported OSA 
was compared to data taken from the polysomnogram and recording in the electronic 
medical record to conduct a sensitivity and specificity analysis. Additionally, we 
evaluated individual questions encompassing each category to assess the influence of 
questions driving positive category scores. Additionally, we evaluated individual 
questions separately for COPD cases and controls (defined by pulmonary function: 
GOLD stages 2-4) to determine the utility of the Berlin sleep questionnaire in a COPD 
population.  
3.3.2. Obstructive Sleep Apnea by Polysomnography 
Our primary exposure of interest was OSA and OSA severity. The objective 
diagnosis of OSA was established by previously conducted attended overnight 
polysomnogram (sleep studies) conducted between 2008-2012 on a subpopulation of 
COPDGene National Jewish Health subjects using a computerized recording system 
(Embla, REMbrant version 9, Broomfield, CO, USA) Details from each sleep study was 
ascertained by electronic medical record chart review and all variables acquired merged 
by subject identification number with the existing COPDGene datasets. 
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The polysomnogram consisted of continuous polygraphic recording from surface 
leads. Electroencephalography electrodes were applied at C4-A1, C3-A2, O1-A2, and 
O2-A1 to monitor brain waves. Chin muscle activity was measured by electromyography. 
Eye movements were identified by electrooculography. Oronasal airflow was monitored 
using both a thermocouple (thermistor) and pressure transducer. Thoracic and abdominal 
impedance belts were used to measure respiratory effort. Oxyhemoglobin saturation in 
the blood was measured through pulse oximetry. A tracheal microphone was used to 
monitor snoring. Sensors were placed on each leg to monitor leg movements as well as a 
sensor to monitor sleep position. 
Polysomnographic recordings were scored manually by trained polysomnographic 
technologists with sleep stages and arousals identified using standard criteria [170] and 
respiratory events scored in accordance with the American Academy of Sleep Medicine 
(AASM) [171]. An apnea was defined as complete cessation of airflow for 10 seconds or 
more identified from the thermocouple (thermistor) channel, accompanied with an 
arousal and/or a ≥4% oxyhemoglobin desaturation identified on SpO2 channel. A 
hypopnea was defined as an abnormal respiratory event lasting at least 10 seconds with at 
least a 30% decrease in thoracoabdominal movement on thoracic/abdominal impedance 
belts or decrease in airflow identified on the pressure transducer channel as compared 
with baselines and oxyhemoglobin desaturation of ≥4% or 50% decrease in 
thoracoabdominal movement or airflow, as compared with baseline with an associated 
arousal on EEG.  
Different detection methods were used to identify respiratory events as research 
has shown that the nasal cannula/pressure transducer system is the best noninvasive 
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method to detect minimal changes in airflow (hypopnea) during a nocturnal 
polysomnogram [172-175]. The average number of episodes of apnea and hypopnea per 
hour of sleep (apnea/hypopnea index, AHI) was calculated as the summary measurement 
of sleep-disordered breathing. 
3.3.3. Additional Polysomnographic Measures 
Severity of OSA was classified by AASM [171]  as an AHI  ≥ 5 -14 indicating 
mild OSA, AHI  ≥ 15-29 indicating moderate OSA and AHI  ≥ 30 indicating severe 
OSA. The total continuous sleep time each subjects’ oxygen saturation remained below 
88% was collected. In addition, we collected data on each subjects’ lowest oxygen 
saturation during the study and baseline oxygen saturation at sleep onset.  
3.3.4. Oxygen Re-saturation 
Using the digital recording of the SpO2 channel of the polysomnogram, we 
created a novel variable capturing re-saturation time for each subject that had available 
sleep study recordings. Previous studies have postulated that intermittent hypoxia is 
analogous to ischemia-reperfusion injury where damage occurs when blood flow to a 
hypoxic tissue is restored [40-42] more specifically, the inflammatory damage from 
hypoxia is from the re-saturation phase rather than the de-saturation phase [39]. 
 To determine if re-saturation time in subjects with OSA was different from 
subjects with differing pulmonary abnormalities, we examined each sleep study and 
determined the amount of time it took for a subject to re-saturate after an apneic or 
hypopneic event by counting the seconds from peak de-saturation to the return to baseline 
for that subject. Baseline was defined as the SpO2 preceding each event. Each re-
saturation curve was viewed to assess variability of the measure within each subject using 
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repeated measures ANOVA and when applicable, evaluated the differences in re-
saturation time between Overlap syndrome groups. The variable was collected pre-
treatment in stages one, two, and REM sleep where available. Figure 3.1. Illustrates the 
method for creating the re-saturation variable 
COPD, specifically the emphysema type has reduced surface area available for 
gas exchange as shown by a reduction of the diffusing capacity of carbon monoxide 
(DLCO) [35] which we anticipated presence on polysomnogram as longer time interval 
from peak desaturation to re-saturation to baseline on the SpO2 channel versus a subject 
with only OSA who would have normal surface area for gas exchange therefore shorter 
interval from peak desaturation to re-saturation to baseline on the SpO2 channel.  
In assessing re-saturation, it was important to consider subjects with diabetes as 
HbA1c is increased in diabetic subjects [177-179] and there is 10X the affinity of oxygen 
to glycosylated hemoglobin compared to non-glycosylated hemoglobin [180]. This could 
impact the re-saturation curve as I would expect subjects with OSA and type II diabetes 
(higher H1A1c) levels to have a slower curve or comparable to subjects with emphysema 
   
    Figure 3.1. Method for Creating Re-saturation Variable from Polysomnogram       
    Figure adapted from: A. Avidan [176]. 
Baseline 
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because of reduced release of oxygen from glycosylated hemoglobin to tissues creating 
longer time for free oxygen molecules to attach to hemoglobin.  
Additionally, one study found that an increase in HbA1c levels lead to an 
overestimation of arterial oxygen saturation by pulse oximetry in type II diabetic patients 
and this difference increased by greater HbA1c levels [181]. It has been suggested that 
type II diabetic subjects with poor glycemic control have an accelerated advanced 
glycation end products (AGES) in the skin collagen [182] and may emit light by 
absorbing specific wavelengths and interfere with accuracy of pulse oximetry [183]. 
Given the increased prevalence of diabetes in OSA [151-153], it was important for us to 
consider the possible effect diabetes would have on the re-saturation time as subjects with 
OSA and diabetes could have comparable re-saturation times as those in a chronic 
hypoxic state.  
Two additional variables which were considered included anemia and heart 
failure. In anemic patients, the reduction of oxygen carrying capacity of the blood may 
lead to tissue hypoxia and elevated 2,3 DPG levels [62] thus creating a curve on re-
saturation similar to a subject with emphysema, biasing our results. Heart failure patients 
have also been found to have higher levels of 2,3 DPG reducing the affinity of oxygen to 
hemoglobin in the lungs [63] which could distort our results if heart failure patients were 
in the OSA only group.  
3.4. OVERALL DESIGN AND METHODS 
For specific aims 1 and 2 analyses were conducted using a layered approach of 
three epidemiological study design methodologies: 
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a.) full COPDgene cohort analysis (n=10,192); evaluating self-reported OSA and 
outcomes. 
b.) single site epidemiological analysis; Berlin sleep questionnaire in the National 
Jewish Health clinical site (n=983); evaluating OSA and outcomes. 
c.) National Jewish Health clinical sample (n=406 and n=98); sample of the 
National Jewish Health subjects with overnight polysomnograms; evaluate objective 
OSA and outcomes.Within this group of subjects, we were able to access the full 
polysomnogram from the electronic medical record to create the re-saturation variable.  
Multicollinearity was assessed using a generalized linear model and evaluating 
the correlation matrix for categorical covariates and Pearson’s correlation used to 
evaluate relationships between continuous variables. Chi-square test was used to evaluate 
categorical variables while independent t test or ANOVA was used for continuous 
variables with normal distribution or Wilcoxon sum rank test for continuous, non-
normally distributed variables. Fisher’s exact test for categorical variables with small cell 
sizes was used and non-parametric versions of all tests if we had a small sample size n ≤ 
20. Jonckheere Terpstra test was conducted to test the trend of categorical variables 
across GOLD stages given ordered nature of the variable or Kruskal Wallis test for trend 
when order could not be reasonably assumed. 
For analyses where CT emphysema was the outcome variable and the full 
COPDgene cohort was utilized, a generalized linear mixed model was used to account for 
possible center effects of recruitment of differing patient populations and differences in 
scanner by clinical sites. Later pairwise comparisons were conducted between groups 
using Bonferroni correction or contrast statements as appropriate. All analyses were 
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conducted using SAS 9.3 (Cary, N.C). Table 3.1 summarizes the primary outcomes and 
covariates that were used in the analyses. 
High cholesterol and statin use were correlated as 86% of subjects with high 
cholesterol are on statins compared to 24% with high cholesterol, p<0.0001 (data not 
shown). In models where both variables were considered, it was determined to use the 
variable identified as important to adjust for given the hypothesis being tested. Care was 
taken to ensure that collinearity did not inflate standard errors of the parameter estimates 
or change directionality of parameter estimates.  
3.4.1. Design and Methods for Specific Aim 1 
Contrary to current definitions of COPD, we considered various types of 
pulmonary disease (pulmonary abnormalities) and were defined as follows: pulmonary 
function reduction as assessed by post bronchodilator spirometry (GOLD stages 2-4), 
emphysema defined as ≥5% total emphysema identified on chest computed tomography 
scan with cutoff for % emphysema based on prior research [164] and chronic bronchitis 
defined by standard protocol as chronic productive cough for 3 months in each of 2 
successive years in a patient of whom other causes of productive chronic cough have 
been excluded [22]. The primary independent (predictor) variables were OSA and OSA 
severity. 
All models were adjusted for similar covariates as outlined in Table 3.1. 
Additional covariates included in the models were as follows: In model of self-reported 
OSA and GOLD stages 2-4, additional covariates included gender, BMI, statin use, and 
use of bronchodilators.  
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In evaluating physician diagnosed OSA from polysomnography and GOLD stages 
2-4, additional covariates included gender, BMI, statin use, and use of bronchodilators. 
Bronchodilators are a mainstay of COPD treatment and include β-adrenergic agonists, 
anticholinergics, and methylxanthines. β-adrenergic agonists are effective in alleviating 
symptoms and they can produce significant increases in FEV1 [184-185]  Their effect is 
achieved through smooth-muscle relaxation, resulting in improved lung emptying, 
reduced thoracic gas volume and residual volume, and lessened dynamic hyperinflation. 




Primary Outcome Primary Explanatory Variable Common Covariates in Initial 
Models 
Specific Aim 1   
a. COPD (GOLD 2-4) 
b. Percent Emphysema of total 
lung 
c. Chronic Bronchitis 
Physician diagnosed OSA(self-
report), OSA(polysomnogram) 
Age, race, current smoking, 
pack years, diabetes, steroid 
use. 
Specific Aim 2   
 
a. Coronary Calcium/Thoracic 




Physician diagnosed OSA (self-
report), OSA (polysomnogram) 
 
Age, gender, race, current 
smoking, pack-years, BMI, 
diabetes, hypertension, 
hyperlipidemia, diabetes, 
steroid use, statin use 
*Pre-existent CVD excluded 
Specific Aim 3   
a. Re-saturation; time interval 
from peak de-saturation to 








Age, gender, race, current 
smoking, pack-years, diabetes. 
*Subjects with Anemia 
excluded 
*Re-saturation assessed pre-
treatment in split night 
studies(stage 1,stage 2 
&REM) 
Additional Analysis   
Sensitivity and Specificity of OSA OSA self-reported Physician 
Diagnosed  
Berlin Sleep Questionnaire 
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In analyses evaluating the relationship between OSA and emphysema, only 
univariate analyses of OSA by varying definitions (self-report, Polysomnography) were 
conducted and not statistically significant.  
For model evaluating self-reported OSA and chronic bronchitis, additional 
covariates included bronchodilator use, BMI, FEV1pp, and FVCpp. In model evaluating 
physician diagnosed OSA defined by polysomnography and chronic bronchitis, 
additional covariates included bronchodilator use, BMI and pulmonary function.   
Criteria for covariate inclusion in the multivariable models were statistical 
significance of covariate and outcome in univariate analysis at a p value of <0.10.  All 
significant covariates were included in the full model and a manual backward stepwise 
approach was utilized. Each excluded variable was examined to see if it influenced the 
relationship between OSA and the outcome by changing the beta estimate of OSA by 
more than 10%. Covariates that changed the beta estimate by more than 10% were 
maintained in the model as confounders.  
Model fit was assessed using log likelihood (logistic model) for nested models or 
AIC for non-nested models. Sample size calculations for testing difference in pulmonary 
abnormalities (GOLD stages 2-4, Chronic Bronchitis, Emphysema) in subjects with OSA 
compared to no OSA were calculated based on Cohen et al [186-187].  
3.4.2. Sample Size for Specific Aim 1 
Evaluating the relationship between OSA using a logistic regression of a binary 
response variable (Y) on a binary independent variable (X) with a sample size of 100 
observations of which 25% are in the group X=1 achieves 85% power at a 0.05 
significance level to detect a change in Prob (Y=1) from the baseline 
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value of 0.050 to 0.47. This change corresponds to an odds ratio of 3.0. With greater 
sample size, we will have more power to detect the same effect [188, Figure 3.2.]. 
 
3.4.3. Design and Methods for Specific Aim 2 
The primary dependent (outcome) variables (Coronary arterial calcium, thoracic 
arterial calcium) were measured. The dependent variable (CAC) was categorized and 
defined as subjects with any CAC (>1) versus no CAC (0). CAC was further categorized 
using established clinical cut points: 0, 1-100, 101-400, and >400 [189]. TAC was 
dichotomized as presence of TAC (>1) or no TAC (0). There are no established clinical 
cut points for TAC so the variable was separated into quartiles to evaluate severity for 
ease of clinical interpretation. 
Prior research has shown that lipid lowering therapy (statins) reduced plaque 
progression [190-192] so this variable was considered when evaluating OSA and 
CAC/TAC. Criteria for covariate inclusion in the multivariable model was statistical 
significance of the covariate and outcome in univariable analysis at a p value of <0.10.  
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All significant covariates were included in the full model and a manual backward 
stepwise approach was utilized. Each excluded variable was examined to see if it 
influenced the relationship between the exposure and outcome by changing the beta 
estimate of OSA by more than 10%. Covariates that changed the beta estimate by more 
than 10% were maintained in the model as confounders. Interactions between OSA and 
the various pulmonary abnormalities were assessed to examine the influence each may 
have on the relationship between OSA and calcification measures.  
Model fit was assessed using log likelihood for nested models of CAC and TAC 
(logistic model) or AIC for non-nested models. Sample size calculations for testing the 
association between OSA and the dependent variables were calculated based on Cohen et 
al [186-187].  
 
Evaluating the relationship between OSA using a logistic regression of a binary 
response variable (Y) on a binary independent variable (X) with a sample size of 117  
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observations of which 28% are in the group X=1 achieves 80% power at a 0.05 
significance level to detect a change in Prob (Y=1) from the baseline value of 0.050 to 
0.20. This change corresponds to an odds ratio of 2.0. With greater sample size, we will 
have more power to detect the same effect [188, Figure 3.3.]. 
3.4.5. Design and Methods for Specific Aim 3 
The primary dependent (outcome) variable (re-saturation) is a novel variable 
created from the physiologic signal from the SpO2 channel of previously collected 
polysomnograms from COPDGene National Jewish Health subjects. The details of the 
method for collection of the re-saturation variable was outlined previously. The re-
saturation variable was taken from stages 1, 2, and REM sleep. Two different baseline 
oxygen levels were collected. The first measurement was baseline oxygen level at sleep 
onset from beginning of the study. The second baseline measurement was taken 
immediately prior to the event (highest SpO2 level). Variability of the re-saturation 
measurement was evaluated by scanning each subject’s pre-treatment (pre positive 
airway pressure or pre oxygen therapy initiation) study data to reduce the influence of 
treatment on the re-saturation curve after an apneic or hypopneic event.  
Each study was scanned in its entirety and variability in the re-saturation measure 
within subjects was assessed (length and type: apnea versus hypopnea) using repeated 
measures ANOVA. The average time for re-saturation was calculated for each subject 
with available sleep records. We were blinded to pulmonary abnormalities while pulling 
the re-saturation variable to reduce potential bias during data collection. Pulmonary 
abnormalities were identified after data collection was completed. The re-saturation 
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variable was calculated in subjects with OSA and different pulmonary abnormalities 
(Emphysema only, chronic bronchitis only, defined a priori). 
The primary independent (predictor) variable was average re-saturation time in 
seconds. Other variables recorded from the polysomnogram and examined were total 
minutes of continuous sleep time spent below a SpO2 88% and lowest SpO2 recorded 
during the sleep study. Studies have found various measurements of oxygenation during 
sleep are related to plaque formation [193-194], however the relationship did not hold in 
multivariable models adjusted for age and AHI [194].   
3.4.6. Sample Size for Specific Aim 3  
When assessing the difference in re-saturation time by Overlap syndrome 
categories (OSA and OSA+Emphysema), a sample size of 4 (2 per group) achieves 80% 
power to detect a change of 5 seconds with a two-sided significance level is 0.05 [188, 
Figure 3.4.]. I will be able to detect an even smaller change with a larger sample size.  
 
 
Figure 3.4. Power Analysis for Specific Aim 3 
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3.5.1 Design and Methods for Sensitivity and Specificity Analysis 
The Berlin Sleep Questionnaire was sent out to 983 National Jewish COPDGene 
subjects who consented to be re-contacted for future studies. Of the 983 questionnaires 
and consents sent out, n=26 questionnaires came back due to incorrect addresses, n=40 
sent back consent without questionnaire, and n=5 refused to participate for a final sample 
of n=335 for a response rate of 44%. Of the subjects who consented to be included in the 
study (ancillary sleep study data collection) 110 were identified as having a sleep study 
conducted at National Jewish Health with 98 available sleep study records (sleep 
summary data) in the electronic medical record database however, positive identification 
of OSA or no OSA was verified on all subjects giving consent (n=406).  We examined 
the validity of self-reported OSA collected through medical history questionnaire in 
COPDGene and high risk OSA identified from Berlin sleep questionnaire on subjects 
from the National Jewish Health and compared both measures to objective sleep study 
data. Sensitivity and specificity were calculated. 
3.6. STRENGTHS AND LIMITATIONS 
3.6.1. Strengths 
Strengths of the study include expanding existing knowledge of the hypoxic 
pathway which precludes CVD by evaluating a novel variable; re-saturation and whether 
re-saturation varies within subjects and differences in re-saturation time by Overlap 
syndrome groups. Secondly, we will be able to examine the relationship between OSA 
and coronary/thoracic calcium measures and identify the influence of pulmonary 
abnormalities. Increased knowledge of this pathway will assist with identifying patients 
at higher risk for atherosclerosis and provide physicians with a new clinical measure 
which could be readily programmable and available on future polysomnographic 
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summary reports. Lastly, this will be the first study evaluating the utility of Berlin sleep 
questionnaire in a COPD population as well as assess validity of self-reported OSA from 
the COPDGene medical history questionnaire. 
3.6.2. Limitations 
As with any proposal, there are potential limitations. As this is a cross sectional 
study, we will not be able to determine a temporal relationship as data was collected at 
the same point in time however; we will be able to assess associations between variables 
and generate hypotheses for future research studies. Secondly, given the cross sectional 
nature of the data, we could have incidence-prevalence bias as we will not know duration 
of disease, and prevalence is, of course, a measure of both incidence and duration of 
disease. Lastly, we could have survival bias as subjects with more severe OSA and/or 
more severe pulmonary compromise could have higher rates of mortality thus leaving us 
with less subjects. Despite these possible biases, we will be able to examine the various 
relationships that will generate hypotheses for future longitudinal studies in the 
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CHAPTER IV 
ASSESSING MISCLASSIFICATION OF SELF-REPORTED OBSTRUCTIVE 
SLEEP APNEA IN THE COPDGENE COHORT: WHAT IS THE UTILITY OF 
THE BERLIN SLEEP QUESTIONNAIRE IN A COPD POPULATION 
4.1. ABSTRACT 
The presence of both Obstructive sleep apnea (OSA) and Chronic Obstructive 
Pulmonary Disease (COPD) or Overlap Syndrome place subjects at greater risk of 
prolonged oxygen desaturation at night than those with OSA alone and atherosclerosis 
development in OSA and COPD have been hypothesized to be caused by inflammatory 
pathway signaling mediated by hypoxia [12]. A simple screening tool is needed to 
identify OSA in subjects with COPD to reduce the burden of costly and at times 
unnecessary sleep studies. The objective of our study was to examine the utility of self-
reported OSA and OSA identified by Berlin sleep questionnaire in a COPD population.  
Self-reported OSA has moderate sensitivity (64.3%) and good specificity (82.8%) 
for identifying subjects with and without OSA however the Berlin sleep questionnaire 
had poor sensitivity (42.1%) and moderate specificity (76.6%). Sensitivity and specificity 
were further reduced in subjects with COPD. The Berlin Sleep questionnaire has poor 
validity for utilization in COPD populations however given the right set of questions, 
self-report could be a useful screening tool for OSA. 
4.2. INTRODUCTION 
Obstructive sleep apnea (OSA) is characterized by repeated episodes of upper 
airway collapse during sleep with associated oxygen desaturations and sleep 
fragmentation affecting an estimated 3-7% of adults in the general population [2] and is 
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related to incident CVD [3]. COPD has become the third leading cause of death behind 
CVD and cancer [4] affecting between 10 and 20 million adults [5]. Several studies have 
demonstrated that an obstructive pattern on spirometry is an independent risk factor for 
myocardial infarction, cardiovascular mortality, and stroke [6-9] in samples of the 
general population.  
In 1985, Flenley identified the concurrence of OSA and COPD and devised the 
name Overlap Syndrome (OS) [10] to describe the condition. Today, prevalence has been 
documented to occur anywhere from 1% in population studies [11-12] to 40% in clinical 
studies [13] and has been shown to increase the risk for cardiovascular disease mortality 
[13].  Specifically, atherosclerosis development in OSA and COPD have been 
hypothesized to be caused by inflammatory pathway signaling mediated by hypoxia [12] 
and subjects with Overlap Syndrome are at greater risk of prolonged oxygen desaturation 
at night than those with OSA alone and the degree of airflow obstruction, as measured by 
FEV1/FVC, correlates with risk of prolonged hypoxemia[14].  
Subjects are commonly referred for a sleep study to rule out OSA based on 
symptoms of daytime sleepiness, snoring, witnessed apnea, and morning headaches to 
name a few. Subjects with COPD have similar complaints such as morning tiredness and 
excessive daytime sleepiness [201-203]. In subjects with chronic bronchitis, the most 
common complaints are snoring, not feeling rested after full night’s sleep, and worry of 
witnessed apnea.  
Questionnaires are cost effective screening tools that can possibly identify 
subjects with OSA. Specifically, the Berlin sleep questionnaire and has been widely used 
in various populations. Sensitivity and specificity of the Berlin Sleep questionnaire was 
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documented in a general clinic population as 86% and 77% respectively [170] however, 
its clinical utility has varied in different populations studied. The Berlin Sleep 
questionnaire has never been validated in a COPD population where presence of similar 
symptoms may alter the sensitivity and specificity of the screening instrument. Self-
reported OSA has never been validated as sleep research tends to focus on use of the gold 
standard (sleep studies) to identify subjects with OSA [196]. Sleep studies are extremely 
costly so it is important to determine whether questionnaire data is a suitable alternative 
to identifying subjects with and without OSA. The primary aim of this study is to 
determine the sensitivity and specificity of the Berlin Sleep Questionnaire and self-
reported data from medical history questionnaire in patients from a single site center of 
the COPDGene cohort and further examine if there is a difference in sensitivity and 
specificity in subjects with COPD compared to those without COPD.   
4.3. SUBJECTS AND METHODS 
4.3.1. Population 
COPDgene is a multicenter epidemiologic case-control study of 10,192 current 
and former smoking men and women, non-Hispanic White and African American 
between the ages of 45 and 80, with at least a 10 pack year history of smoking. The study 
was designed to study the genetic susceptibility to COPD. Subjects were recruited based 
on presence or absence of COPD as defined by post bronchodilator spirometry 
measurements (forced vital capacity; FVC < 0.70); ndd EasyOneTM spirometer (Zurich, 
Switzerland)  using standard protocol [167] and further characterized by severity using 
forced expiratory volume in one second percent predicted (FEV1pp) as defined by the 
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Global Initiative for Obstructive Lung Disease (GOLD stage) criteria [163]. COPD was 
defined as subjects in GOLD stages 2-4 and controls were defined as GOLD stage 0. 
A single site sample of COPDGene subjects from National Jewish Health were 
recruited for an ancillary study collecting additional sleep data from electronic medical 
chart review. Approval was obtained from the National Jewish Health Institutional 
Review Board protocol number HS 2738 and COPDGene executive committee to 
conduct the ancillary study.  
Four hundred and six subjects consented to be included in the study however only 
335 returned the Berlin questionnaire with the consent form. Of the subjects returning the 
mailing, 98 were identified as having a previously conducted attended overnight 
polysomnogram (sleep study) conducted between 2008-2012 at National Jewish Health 
using the computerized recording system (Embla, REMbrant version 9, Broomfield, CO, 
USA) Details from each sleep study were ascertained by electronic medical record chart 
review. All subjects were confirmed as having a positive or negative OSA diagnosis 
through electronic medical chart review irrespective whether or not the sleep study was 
conducted at National Jewish Health.  
The polysomnogram consisted of continuous polygraphic recording from surface 
leads. Electroencephalography electrodes were applied at C4-A1, C3-A2, O1-A2, and 
O2-A1 to monitor brain waves. Chin muscle activity was measured by electromyography. 
Eye movements were identified by electrooculography. Oronasal airflow was monitored 
using both a thermocouple (thermistor) and pressure transducer. Thoracic and abdominal 
impedance belts were used to measure respiratory effort. Oxyhemoglobin saturation in 
the blood was measured through pulse oximetry. A tracheal microphone was used to 
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monitor snoring. Sensors were placed on each leg to monitor leg movements as well as a 
sensor to monitor sleep position. Polysomnographic recordings were scored manually by 
trained polysomnographic technologists with sleep stages and arousals identified using 
standard criteria [171] and respiratory events scored in accordance with the American 
Academy of Sleep Medicine (AASM) [172].  
An apnea is defined as complete cessation of airflow for 10 seconds or more 
identified from the thermocouple (thermistor) channel, accompanied with an arousal 
and/or a ≥4% oxyhemoglobin desaturation identified on SpO2 channel. A hypopnea is 
defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% 
decrease in thoracoabdominal movement on thoracic/abdominal impedance belts or 
decrease in airflow identified on the pressure transducer channel as compared with 
baselines and oxyhemoglobin desaturation of ≥4% or 50% decrease in thoracoabdominal 
movement or airflow, as compared with baseline with an associated arousal on EEG. 
OSA was defined as an AHI of ≥ 5 with severity classified by AASM [172] as 
follows: AHI ≥ 5 -14 (mild), an AHI ≥ 15-29 (moderate) and AHI ≥ 30 (severe). Other 
variables ascertained from medical records included the total continuous sleep time each 
subjects’ oxygen saturation remained below 88%, lowest oxygen saturation during the 
study and baseline oxygen saturation at sleep onset. 
The determination of high and low risk sleep apnea was based on the 
questionnaire responses in three symptom categories. For category 1, a positive response 
is defined as persistent symptoms (3 to 4 times/wk.) in two or more questions about their 
snoring. For category 2, a positive response is defined as persistent (3 to 4 times/wk.) 
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wake time sleepiness, drowsy driving, or both. For category 3, a positive response is 
defined as a history of high blood pressure or a body mass index more than 30 kg/m2.  
To be considered at high risk for obstructive sleep apnea, a patient had to qualify 
as indicated by a positive score: ≥2 in at least two symptom categories. Subjects denying 
persistent symptoms or only qualifying in one symptom category: positive score <2 were 
considered low risk. A copy of the Berlin Sleep questionnaire is included as an 
attachment (Appendix A).  
OSA via self-report was determined by a “yes” response to a series of questions: 
Have you ever been told you have sleep apnea and / or have you ever been physician 
diagnosed with sleep apnea? 
4.4. STATISTICAL METHODS  
We assessed the overall validity of the Berlin Sleep questionnaire and self-
reported OSA by calculating sensitivity and specificity of the high risk OSA identified by 
Berlin sleep questionnaire and OSA identified by self-report and compared both to the 
gold standard (polysomnogram) [196]. We further calculated sensitivity and specificity of 
both measures separately in subjects with and without COPD.  
4.5. RESULTS 
One hundred and sixty-one (48.1%) subjects were identified as high risk for OSA 
in the entire sample. Evaluating the frequency of subjects identified as positive in each 
category, we found that 141 (87.6%) were positive in category representing snoring and 
apnea (category one), 110 (68.3%) subjects were positive in category representing 
daytime sleepiness/fatigue (category two), and 130 (80.8%) were positive for category 
representing obesity and hypertension (category three).  
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Examining individual questions defining category one, a high percentage of 
subjects identified snoring, specifically frequent snoring and snoring bothers others 
(Table 4.1.). Of subjects with positive response in category two, 72.7% of subjects 
responded feeling tired/fatigued and not up to par while awake most of the week. 
Evaluation of categories and individual questions encompassing the categories in 
subjects with and without COPD yielded interesting results (Table 4.2.). Subjects without 
COPD had a higher percentage of positive results for questions of snoring that bothers 
others (87.5% vs. 64.9%, p<0.01) and apnea (32.1% vs. 18.9%, p<0.05) compared to 
subjects with COPD however within COPD subjects, there was a high percentage of 
positive responses for snoring, snoring frequently, and snoring which bothers others. 
Additionally, within COPD subjects, the positive response in category two appeared to be 
the result of fatigue while awake and not fatigue after sleep (75.7% and 68.9%) contrary 
to what was seen in subjects without COPD.  
In the overall sample, the Berlin sleep questionnaire had poor ability to accurately 
identify subjects with OSA (42.1%) but moderate ability to identify those without OSA 
(77%, Table 4.3.). Specifically in COPD subjects, the Berlin sleep questionnaire had a 
low ability to identify subjects at high risk for OSA (34.5%, Table 4.3.) however the 
ability to identify subjects with OSA was greater in non COPD subjects (55.6%). The 
degree of misclassification was different by COPD case status. Subjects with COPD were 
misclassified 29% of the time and the proportion of non COPD subjects misclassified 
were 31% (data not shown).  
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Evaluating the utility of self-reported OSA in accurately identifying OSA 
yielded surprising results. Self-reported OSA had a better ability to both accurately 
identify subjects with OSA (64.3% Table 4.4.) and without OSA (82.8%). Similar to 
results from the Berlin questionnaire, self-reported OSA had better ability to identify 
subjects with and without OSA in subjects without COPD (64.3% and 88.4% in non 
COPD subjects compared to 62.5% and 82.9% in COPD subjects, respectively). Contrary 
to what we saw using the Berlin sleep questionnaire, self-reported OSA was differentially 
misclassified with a higher proportion of COPD subjects being misclassified compared to 
non-COPD subjects (22% and 17% respectively, data not shown).  
   Table 4.1. Berlin Questionnaire Responses in Entire Sample  




High Risk for OSA (2 out of 3 positive responses) 161 (48.1) 
  
Category One: Snoring and Apnea 
  
  
      141 (87.6) 
Do you snore? 
Snoring louder than talking 
Snoring 3-4 times per week or more 
Snoring bothers others 
Quit breathing during sleep >3-4 times per week 
      145 (90.1) 
       74 (46.0) * 
      110 (68.3) * 
      121 (75.2) * 
       43 (26.7) 
  
Category Two: Daytime sleepiness/fatigue 
  
  
      110 (68.3) 
Feel tired or fatigued after sleep ≥3-4 times per week 
Feel tired or fatigued, not up to par during wake time ≥3-4 times per week 
Nodded off or fallen asleep when driving 
     111 (68.9) 
     117 (72.7) 
       42 (26.1) 
  
  
Category Three: Obesity/Hypertension 
  
  
130 (80.8)  
  
Obesity (BMI ≥30) 
Hypertension 
160 (99.4) 
  88 (54.7) 
   * Answered by subjects responding yes to initial question: do you snore? 
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PPV     
(%) 
NPV   
(%) 
Overall     
OSA 42.1 76.6 26.7 86.5 
COPD +   n=161     
OSA 34.5 78.8 26.3 84.6 
COPD –   n=111     
OSA 55.6 72.0 27.8 89.3 
 
  Table 4.2. Berlin Questionnaire Responses by COPD Case Status 
  * Answered by subjects responding yes to initial question: do you snore?   
   COPD+ = subjects identified as GOLD stages 2-4 by spirometry; COPD- = subjects identified      
   as GOLD stage 0 by spirometry. 
 
 
Berlin Questionnaire Items 






High Risk for OSA  




56 (50.5)  
Category One: Snoring and Apnea 
  
61 (82.4) 52 (92.9)  
Do you snore? 
Snoring louder than talking* 
Snoring 3-4 times per week or more* 
Snoring bothers others* 



















Category Two: Daytime sleepiness/fatigue 
  
51 (68.9) 40 (71.4)  
Feel tired or fatigued after sleep ≥3-4 times 
per week 
Feel tired or fatigued, not up to par during 
wake time ≥3-4 times per week 

















Category Three: Obesity/Hypertension 
  
62 (83.8) 43 (76.8)  













We sought to evaluate the utility of the Berlin sleep questionnaire to identify OSA 
in a single site sample of the COPDGene cohort and further determine the validity of this 
screening tool to identify OSA in subjects with COPD. Additionally, we examined the 
utility of self-reported OSA via questionnaire to accurately identify OSA in our 
population.  
Overall, the questionnaire had poor ability to identify subjects with OSA in the 
entire cohort with further reduction of sensitivity within COPD subjects (34.5% vs. 55.6 
for COPD cases and controls respectively). This could be a reflection of the high number 
of false negatives and false positives in our study.  
COPD subjects had a high percentage of subjects giving a positive response in 
category 3; 84.6%, Table 4.2.). Upon further evaluation we found that specifically 
subjects with COPD had a greater percentage of subjects giving positive responses to 
snoring frequency and feeling fatigue/sleepy during the day. These results were different 
in non COPD subjects where the percentage giving a positive response to feeling 
fatigue/sleepy after sleep and feeling sleepy/fatigued during the day were similar (46.0%, 
46.9%).  






PPV     
(%) 
NPV   
(%) 
Overall     
OSA 64.3 82.8 55.3 87.5 
COPD + n=194     
OSA 62.5 82.9 54.5 87.1 
COPD –  n=123     
OSA 64.3 88.4 62.1 89.4 
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It is possible that COPD subjects present with similar symptoms of daytime 
sleepiness and fatigue as subjects with OSA originating from different etiologies. It has 
been hypothesized that inflammation from bronchitis affects both the upper and lower 
airways. Bronchitic symptoms such as cough and sputum production may result in 
sleeping disturbances that could contribute to general daytime tiredness [201-203]. A 
study done by Larrson and colleagues found that snoring symptoms related to obstructive 
sleep apnea occur more frequently in bronchitic subjects [31]. The same group found 
there was a significant relationship between chronic bronchitis and snoring with daytime 
sleepiness (OR=2.74, 95% CI 1.93-3.89).  
Poor sleep quality in subjects with Emphysema are indicated by subjective 
complaints of insomnia (difficulty falling and staying asleep), morning sleepiness, early 
awakenings, and excessive daytime sleepiness [205]. Cormick and coworkers questioned 
patients with emphysema about perception of sleep quality and found that 72% 
complained of daytime sleepiness [205], however loss of lung function is not correlated 
to bronchitis symptoms.  
In our study, 84.6% percent of COPD subjects gave a positive response for 
category three (obesity/hypertension) with greater percentage of positive responses 
occurring for obesity. This is not surprising given the greater number of subjects with less 
severe pulmonary compromise in our sample possible yielding less caloric expenditure as 
happens in subjects with more severe COPD [204].   
4.7. CONCLUSION 
In conclusion, the Berlin Sleep questionnaire has poor sensitivity and specificity 
in identifying and ruling out OSA in subjects with COPD. The reduced specificity is 
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likely due to the high number of false positives reflected by similar symptoms identified 
in OSA and COPD stemming from dissimilar etiologies. Interestingly, we found that our 
self-reported questionnaire data had an overall moderate sensitivity (64.3%) and high 
specificity (82.8%) for identifying and ruling out OSA with greater specificity noted in 
non COPD subjects (88.4%) showing that self-reported data can be as useful in ruling out 
OSA when structuring questions appropriately.   
However given the differential misclassification noted in our study, it would be 
beneficial to develop a screening tool explicit to COPD subjects which has the ability to 
differentiate between symptoms related to OSA and COPD in order to accurately rule out 
OSA diagnosis in a COPD population and reduce unnecessary sleep studies as these 
studies are pricey and time consuming.  The development of an OSA screening tool 
specific to COPD is necessary to assist physicians with identifying subjects at risk for 
OSA as presence of overlap syndrome increases CVD mortality [13] and will likely 
increase given current reports of underestimation of OSA in the population and high 
number of smokers [16-17] likely to develop COPD. A simple yet valid screening tool is 
the first step to reducing financial burden and adverse outcomes in this population thus 
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CHAPTER V 
ASSESSING OVERLAP SYNDROME IN THE COPDGENE COHORT USING 
DIFFERENT PULMONARY ABNORMALITIES 
5.1. ABSTRACT 
The presence of both Obstructive Sleep Apnea (OSA) and Chronic Obstructive 
Pulmonary Disease (COPD) or Overlap Syndrome has been shown to occur anywhere 
between 1-40% depending on population studied [11-12, 13].  Studies have attempted to 
examine the relationship between OSA and COPD show conflicting results. All of the 
studies examining this relationship have used pulmonary function measurements in 
defining COPD. Research has shown that COPD is a heterogeneous disease with clinical, 
functional, and radiological presentation varying from patient to patient thus in order to 
fully evaluate this relationship it is important to consider COPD subtypes.   
The objective of this study was to evaluate the relationships between OSA and 
differing COPD subtypes (GOLD stages 2-4, Chronic Bronchitis, and Emphysema) using 
both self-reported OSA and objective OSA.  
OSA is not related to GOLD stages 2-4 or Emphysema however, subjects with 
chronic bronchitis have increased odds of diagnosed OSA (OR=2.68, 95% CI=1.09-6.64, 
p<0.05).  
5.2. INTRODUCTION 
Obstructive sleep apnea (OSA) is characterized by repeated episodes of upper 
airway collapse during sleep with associated oxygen de-saturations and sleep 
fragmentation affecting an estimated 3-7% of adults in the general population [2] and is 
related to incident Cardiovascular Disease (CVD) [3]. Chronic obstructive pulmonary 
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disease (COPD) has become the third leading cause of death behind CVD and cancer [4] 
affecting between 10 and 20 million adults [5] and has also been implicated as an 
independent risk factor for CVD [6-9].   
The concurrence of OSA and COPD or Overlap Syndrome (OS) has been shown 
in a clinical population to be as high as 40% [13] and increases the risk for cardiovascular 
disease mortality [13]. One of the hypothesized mechanisms for CVD development in 
OSA and COPD is hypoxic mediated inflammation [12]. Subjects with Overlap 
Syndrome are at greater risk of prolonged oxygen de-saturation at night than those with 
OSA alone and degree of airflow obstruction, as measured by FEV1/FVC, correlates with 
risk of prolonged hypoxemia [14]. 
Current research evaluating OSA and COPD show conflicting results. Smaller 
studies in clinic samples documented a greater prevalence of OSA in COPD and vice 
versa [19, 11] while larger population studies showed no association between OSA and 
COPD [20, 21] however; these were limited by defining COPD with pulmonary function. 
This is a serious limitation as COPD is a heterogeneous disease whose clinical, 
functional, and radiological presentation varies from patient to patient despite a similar 
degree of airflow limitation and the current definition may or may not encompass 
emphysema and/or chronic bronchitis which may relate to OSA differently.  
This study will first evaluate the relationships between self-reported OSA and 
differing COPD subtypes (GOLD stages 2-4, Chronic Bronchitis, and Emphysema) in the 
entire COPDGene population. Next, in a sample of COPDGene participants, we will 
examine the association between objective measures of OSA and COPD subtypes.  
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5.3. SUBJECTS AND METHODS 
COPDgene is a multicenter epidemiologic case-control study of 10,192 current 
and former smoking men and women, non-Hispanic White and African American 
between the ages of 45 and 80, with at least a 10 pack year history of smoking. The study 
was designed to study the genetic susceptibility to COPD. Subjects were recruited based 
on presence or absence of COPD as defined by post bronchodilator spirometry 
measurements (forced vital capacity; FVC < 0.70); ndd EasyOneTM spirometer (Zurich, 
Switzerland)  using standard protocol [167] and further characterized by severity using 
forced expiratory volume in one second percent predicted (FEV1pp) as defined by the 
Global Initiative for Obstructive Lung Disease (GOLD stage) criteria [163].  
In the full COPDgene cohort, only subjects who had complete data available and 
met the definitions for the different COPD subtypes were evaluated to assess the 
relationships between self-reported OSA and different COPD subtypes (n= 5542, Chronic 
bronchitis group; n=8238, Emphysema group; n=8077, GOLD stages 2-4 group). 
A single site sample of COPDGene subjects from National Jewish Health were 
recruited for an ancillary study collecting additional sleep data. Approval was obtained 
from the National Jewish Health Institutional Review Board and COPDGene executive 
committee to conduct the ancillary study.  
Four hundred and six subjects consented to be included in the single site study. Of 
those subjects, 98 were identified as having a previously conducted attended overnight 
polysomnogram (sleep study) conducted between 2008-2012 at National Jewish Health 
using the computerized recording system (Embla, REMbrant version 9, Broomfield, CO, 
USA) Details from each sleep study were ascertained by electronic medical record chart 
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review. All subjects were confirmed as having a positive or negative OSA diagnosis 
through electronic medical chart review irrespective of whether or not the sleep study 
was conducted at National Jewish Health. For the single site analyses, only subjects with 
complete data and met definitions for the different COPD subtypes were included in the 
analyses (n=237, chronic bronchitis group; n=309, Emphysema group; n=317 GOLD 
stages 2-4 group).  
The polysomnogram consisted of continuous polygraphic recording from surface 
leads. Electroencephalography electrodes were applied at C4-A1, C3-A2, O1-A2, and 
O2-A1 to monitor brain waves. Chin muscle activity was measured by electromyography. 
Eye movements were identified by electrooculography. Oronasal airflow was monitored 
using both a thermocouple (thermistor) and pressure transducer. Thoracic and abdominal 
impedance belts were used to measure respiratory effort. Oxyhemoglobin saturation in 
the blood was measured through pulse oximetry. A tracheal microphone was used to 
monitor snoring. Sensors were placed on each leg to monitor leg movements as well as a 
sensor to monitor sleep position. Polysomnographic recordings were scored manually by 
trained polysomnographic technologists with sleep stages and arousals identified using 
standard criteria [171] and respiratory events scored in accordance with the American 
Academy of Sleep Medicine (AASM) [172].  
An apnea is defined as complete cessation of airflow for 10 seconds or more 
identified from the thermocouple (thermistor) channel, accompanied with an arousal 
and/or a ≥4% oxyhemoglobin desaturation identified on SpO2 channel. A hypopnea is 
defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% 
decrease in thoracoabdominal movement on thoracic/abdominal impedance belts or 
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decrease in airflow identified on the pressure transducer channel as compared with 
baselines and oxyhemoglobin desaturation of ≥4% or 50% decrease in thoracoabdominal 
movement or airflow, as compared with baseline with an associated arousal on EEG. 
OSA was defined as an AHI of ≥ 5 with severity classified by AASM [172] as 
follows: AHI ≥ 5 -14 (mild), an AHI ≥ 15-29 (moderate) and AHI ≥ 30 (severe). Other 
variables ascertained from medical records included the total continuous sleep time each 
subjects’ oxygen saturation remained below 88%, lowest oxygen saturation during the 
study and baseline oxygen saturation at sleep onset.  
OSA was determined by a “yes” response to a series of questions: Have you ever 
been told you have sleep apnea and / or have you ever been physician diagnosed with 
sleep apnea? 
All subjects received CT scans using multi-detector CT scanners (at least 16 
detector channels). Volumetric CT acquisitions were obtained both on full inspiration 
(200 mAs), and at the end of normal expiration (50 mAs)[164]. Image reconstruction 
utilized sub-millimeter slice thickness, with smooth and edge-enhancing algorithms. The 
following analyses were performed on segmented lung images, using Slicer 
(www.Slicer.org): total inspiratory and expiratory lung volumes, and relative lung 
volumes falling below attenuation thresholds of −950, −910 and −856 HU. Measures of 
emphysema were reported using the -950HU threshold (%LAA-950) from the inspiratory 
scans with further meeting a threshold value of ≥5 percent emphysema of the total lung 
based on previous work from Zach and colleagues evaluating CT thresholds in non-
smoking controls [165].  
In defining COPD by function, cases were defined by post bronchodilator 
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spirometry as GOLD stages 2-4 and smoking controls defined as GOLD stage 0. Chronic 
bronchitis was defined by standard protocol as chronic productive cough for 3 months in 
each of 2 successive years in a patient of whom other causes of productive chronic cough 
have been excluded [166].  
Smoking status was a created variable of current and former smokers using a 
modified questionnaire taken from the ATS adult respiratory questionnaire [169]. 
Subjects were classified as current smokers if they answered “Yes” to the following 
question: Do you now smoke cigarettes (as of a month ago)? Subjects who did not 
answer “Yes” to the aforementioned question were classified as former smokers. 
Pack-years were calculated using standard questions from the ATS Adult 
Respiratory Questionnaire. The average number of cigarettes smoked per day was 
divided by twenty to convert to packs.    
Age, gender, and race were ascertained from a demographic questionnaire. Body 
mass index was calculated by dividing weight in kilograms by meters squared (kg/m2). A 
medication questionnaire was used to identify all medications (brand name and generic) 
taken by each subject. Covariates such as high blood pressure and high cholesterol were 
defined by self-report as many medications which would have assisted with defining 
covariates are important to adjust for in multivariable models given our specific 
hypotheses. Diabetes was defined by self-reported diabetes and/or use of at least one 
diabetic medication identified on questionnaire. 
5.4. STATISTICAL METHODS  
Means and standard deviations or medians and interquartile ranges are reported 
for all variables as appropriate with comparisons made using students ttest or Wilcoxon 
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sum ranked test for non-normally distributed data or small sample size. Multivariable 
logistic regression models of dichotomous coronary and thoracic calcium measures 
adjusting for covariates were utilized and multinomial logistic used when the 
proportional odds assumption was violated. Jonckheere-Terpstra was used to assess trend 
of prevalent OSA across COPD subtypes and in assessing COPD subtypes across OSA 
severity. All analysis were performed using the SAS system version 9.3 (Copyright (c) 
2002-2008 by SAS Institute Inc., Cary, NC, USA).  
5.5. RESULTS 
5.5.1. Self-Reported OSA 
In the COPDGene cohort, 14% of population have COPD as defined by GOLD 
stages 2-4. Subjects with reduced function (GOLD stages 2-4) are older, former smokers 
with greater accumulated pack year history. Additionally, subjects in GOLD stages 2-4 
have a greater prevalence of self-reported OSA and worse FEV1pp compared to controls. 
Across GOLD stages, there is a significant trend of prevalent self-reported OSA up to 
GOLD stage 3 (p<0.0001, Jonckheere-Terpstra test for trend, Figure 5.1.) but then 
decreases in GOLD stage 4. 
In the COPDGene cohort, 16% of the population have chronic bronchitis, and 
27% have emphysema (Table 5.2.).Subjects with Emphysema are older, have greater 
accumulated pack years of smoking. Subjects with the chronic bronchitis have the highest 
frequency of current smokers and greatest prevalence of OSA.  
In the COPDGene cohort, 12% of subjects’ self-reported physician diagnosed 
OSA (Table 5.3.). Subjects with OSA were older, former smokers with greater 
accumulated pack year history compared to subjects without self-reported OSA.  
 




Table 5.1. Characteristics of Pulmonary Abnormalities in COPDGene 
 
 
 Figure 5.1. Prevalent OSA by GOLD stage 
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These same subjects also weighed more and had a greater prevalence of chronic 
bronchitis and reduction in FEV1pp.  
Evaluating the relationships between self-reported OSA and COPD, we found that 
there was a relationship between self-reported OSA and chronic bronchitis but there was 
not a significant relationship between self-reported OSA and GOLD stages 2-4 or 
emphysema (Table 5.4).  
Table 5.4.  Relationship between Self-reported OSA and Pulmonary   
      Abnormalities 
         Model 1 adjusted for age (p<0.0001), gender (p=0.1461), race (p<0.001), BMI (p<0.05), current     
         smoking (p<0.0001), pack years (p<0.0001), steroid use (p<0.0001), chronic bronchitis  
         (p<0.0001), emphysema (p<0.0001), and bronchodilator use (p<0.0001). * Diabetes confounded  
         by 9% so left out of model. Chronic bronchitis and Emphysema improve model fit and used to  
         adjust for residual confounding.  Model 2 adjusted for age (p<0.05), gender (p=0.1219), race  
         (p<0.0001), current smoking (p<0.0001), pack years (p<0.001), bronchodilator use (p<0.0001),  
     steroid use (p<0.01), and FEV1pp (p<0.0001). FEV1pp included to control for the effects of  
         reduced function on the relationship and also improved model fit. 
 
5.5.2. Physician Diagnosed OSA 
In the sample of subjects from National Jewish, 13% of subjects were GOLD 
stages 2-4 (Table 5.5.). Subjects in GOLD stages 2-4 were older, former smokers with 
greater accumulated pack-year history. Additionally, there was a higher prevalence of 
physician diagnosed OSA in GOLD stages 2-4 compared to controls.  
  
      




95% CI p value 
Self-Report OSA 1.08 0.88-1.32 0.4583 
2 Chronic Bronchitis  
n=5542 
   
Self-Report OSA 1.33 1.10-1.68 <0.01 
3 Emphysema  
n=8238 
   
Self-Report OSA 1.07 0.92-1.26 0.3776 
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Evaluating prevalent diagnosed OSA across GOLD stages, we did not see 
significant trend of increased prevalence of physician diagnosed OSA by increasing 
GOLD stage. (Jonckheere-Terpstra test for trend, p=0.3206, Figure 5.2). In the sample of 
subjects from National Jewish, 37% had emphysema, and 14% had chronic bronchitis 
(Table 5.6.). 
 
Subjects with emphysema are older, have greater accumulated pack years of 
smoking, as well as greater use of medication with exception of statins. Subjects with the 
chronic bronchitis have the highest frequency of current smokers and greatest prevalence 
of OSA and diabetes.  
In the National Jewish population 24% had been physician diagnosed with OSA 
by polysomnogram (Table 5.7.).  
Table 5.5. Characteristics of Pulmonary Abnormalities in COPDGene Cohort 
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Subjects with OSA had less emphysema, greater prevalence of chronic bronchitis 
with similar pulmonary function. Additionally, subjects with OSA had less total lung 
capacity (TLC) compared to subjects without physician diagnosed OSA.  
Further comparing prevalence of pulmonary abnormalities by OSA severity, we 
found that the greatest prevalence of all pulmonary abnormalities were in subjects with 
moderate OSA (Figures 5.3, 5.4. 5.5.) and there was a significant trend in prevalence of 
chronic bronchitis across OSA severity (Jonckheere-Terpstra, p<0.0001, Figure 5.4.) 
which was not seen in the other pulmonary abnormalities (p=0.2481 for emphysema; 
Figure 5.5. and p=0.1258 for GOLD stages 2-4 respectively, Figure 5.3.).  
In multivariable models there was no association between any OSA and the 
GOLD stages 2-4 or emphysema (Table 5.8.) however, there was an association between 
any OSA and chronic bronchitis. Further evaluating effect of severity of OSA, we found 
         Figure 5.2. Prevalent Physician Diagnosed OSA by GOLD stage 
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that subjects with chronic bronchitis were 3.6 times more likely of having moderate to 
severe OSA (95% CI 1.08-12.26, p<0.05) compared to no OSA. 
 
     Table 5.6. Characteristics of Pulmonary Abnormalities in the COPDGene Cohort 
        † indicates significant comparisons between chronic bronchitis and Controls. ‡ indicates significant      
         comparison between emphysema and controls.
Figure 5.3. Prevalence of GOLD stages 2-4 Across OSA Severity 
 





Figure 5.4. Prevalence of Chronic bronchitis Across OSA Severity 
Figure 5.5. Prevalence of Emphysema across OSA Severity 
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    Model 1 adjusted for age at enrollment (p<0.05), BMI (p=0.0771), pack years (0.0831), current smoking      
    (p=0.2030), steroid use (p=0.0984) bronchodilator use (p <0.001), chronic bronchitis (p=0.0766), and     
    emphysema (p<0.0001); Current smoking, BMI and pack years confound relationship by more than 10%  
    so they were left in model. Emphysema and chronic bronchitis included for residual confounding and   
    improved model fit.  Model 2 adjusted for age at enrollment (p=0.6757), gender (p=0.0543), race  
    (p=0.9046), current smoking (p<0.0001), bronchodilator use (p<0.0001) and FEV1pp (p<0.0001). *   









95% CI p value 
Objective OSA 0.57 0.23-1.45 0.2391 
2 Chronic Bronchitis  
n=237 
   
Objective OSA 2.68 1.09-6.64 <0.05 
3 Emphysema  
n=309 
   
Objective OSA *0.62 0.34-1.10 0.1016 
   Table 5.7. Characteristics of Physician Diagnosed OSA 
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There was not a significant relationship between mild OSA and chronic bronchitis as 
compared to no OSA (OR=1.69, 95% CI 0.44-6.52, p=0.4488). 
5.6. DISCUSSION 
The results are unique as this is the first study to completely separate the subtypes 
eliminating the overlap between subtypes such that we can thoroughly evaluate OSA and 
COPD. Other studies have shown conflicting results in examining the relationship 
between OSA and COPD [11, 19-21] however they were limited by analysis on mild 
COPD subjects in addition to defining COPD solely by pulmonary function. The 
COPDGene cohort has large samples of subjects from various GOLD stages as well as a 
large enough study to separate COPD subtypes without compromising statistical 
significance. In this study we found that there was a significant relationship between 
OSA and the COPD subtypes; specifically chronic bronchitis subtype having increased 
risk of OSA (Table 5.6.).  
Possible explanations for our results could be the fact that pulmonary vascular 
remodeling in COPD has been shown to be related IL-18 [82] with expression as early as 
2 days of hypoxia and have been shown to be greater in subjects with chronic bronchitis 
[84].  IL-18 is important as it is a pro inflammatory cytokine that induces the production 
of TNFα [90], which promotes synthesis of IL-6 [91], with subsequent synthesis of CRP 
in the liver [92]. These cytokines have all been shown to be elevated in both COPD and 
OSA [45-45].  
Additionally, Minoguchi and colleagues found that IL-18 levels were significantly 
greater in OSA subjects compared to controls [206]. Prior studies have hypothesized the 
possible protective relationship between OSA and COPD. Animal data have suggested 
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that thoracic inflation increases airway pharyngeal size and stiffness through caudal 
traction on the trachea independently of upper airway muscle activity. In obstructive lung 
disease such as emphysema, the lungs are hyperinflated indicated by high volume 
measures (total lung capacity, functional residual capacity, and residual volume). Several 
studies have shown that during sleep in normal subjects, upper airway resistance 
increases and functional residual capacity decreases. This may explain the lack of 
association between OSA and GOLD stages 2-4 in our study as we found no difference in 
TLC by OSA severity (F=1.77, p=0.1529, data not shown). 
Our study also found that our results were ameliorated when using self-reported 
OSA as the primary explanatory variable compared to the gold standard of physician 
diagnosed OSA by sleep study. In a prior analyses, we found that self-reported OSA had 
a sensitivity of 64.3% and specificity of 82.8% to accurately identify subjects with and 
without OSA (data not published). We also found that self-reported OSA was 
differentially misclassified by COPD case status (22% in COPD cases, 17% in COPD 
controls, respectively. This could explain the increased prevalence of self-reported OSA 
by GOLD stage (Figure 5.1.) and resultant reduction in risk estimates when evaluating 
self-reported OSA and COPD subtypes (Table 5.3.).   
In conclusion, there is a relationship between OSA and COPD subtypes; 
specifically chronic bronchitis. This is an important result as prevalence of Overlap 
syndrome is likely to rise given the increase in obesity and COPD likely to occur in the 
future. Identification of the relationship between OSA and different COPD subtypes is 
the first step to understanding the complicated interactions between these disorders so 
future studies can determine how these relationships impact CVD outcomes. 
                                                                                            74 
  
CHAPTER VI 
OBSTRUCTIVE SLEEP APNEA IS ASSOCIATED WITH CORONARY 
CALCIFICATION INDEPENDENT OF PULMONARY 
ABNORMALITIES 
6.1. ABSTRACT 
The presence of both Obstructive sleep apnea (OSA) and Chronic Obstructive 
Pulmonary Disease (COPD) or Overlap Syndrome place subjects at greater risk of 
prolonged oxygen desaturation at night than those with OSA alone and atherosclerosis 
development in OSA and COPD have been hypothesized to be caused by inflammatory 
pathway signaling mediated by hypoxia however studies are lacking showing the 
relationship between OSA and subclinical atherosclerosis and whether COPD affects this 
relationship.  
The object of our study was to evaluate the relationship between OSA as defined 
by self-report and sleep study measures and coronary and thoracic calcium (CAC and 
TAC) and further determine whether different pulmonary abnormalities affect these 
relationships.  
There is a significant upward trend of prevalent OSA by increased severity of 
CAC (p<0.05) and there is an independent relationship between OSA and (OR= 3.65, 
95% CI=1.02-13.09, p<0.05) CAC in adjusted models.  
6.2. INTRODUCTION 
Approximately 83 million individuals in the United States have cardiovascular 
disease (CVD) and it is the leading cause of death averaging one death every thirty nine 
seconds [1]. Obstructive sleep apnea (OSA) is a common disorder characterized by 
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recurrent upper airway collapse during sleep leading to oxygen de-saturations affecting 
approximately 3-7% of men and 3-5% of women in the general population [2]. Hypoxic 
driven inflammation has been identified as an important pathway in which atherosclerosis 
and subsequent CVD develops in OSA [12]. Smoking is a known risk factor in OSA [18, 
32-33] and can increase inflammation. 
Calcifications are part of the development of atherosclerosis occurring exclusively 
in atherosclerotic arteries and are absent in the normal vessel wall. Both Coronary arterial 
calcium (CAC) and thoracic arterial calcium (TAC) can be detected simultaneously on 
low dose, non-gated computed tomography scans. CAC has been shown to have a strong 
association with risk of future coronary heart disease (CHD) events and mortality [66-72] 
as well as asymptomatic myocardial ischemia [73-75]. TAC has been shown to be 
associated with coronary risk factors [76] and correlates with CAC [110] however; a 
more recent study showed that CAC and TAC may be beneficial in predicting different 
CVD outcomes [111]. CAC has been modestly studied in OSA with conflicting results 
[112-113]. 
The aim of this paper is to evaluate the relationship between OSA and arterial 
calcium measures (CAC and TAC) in a population of smokers. No previous study has 
examined the relationship of OSA and CAC and TAC as detected by computed 
tomography (CT) in a large smoking population based cohort. We performed a cross-
sectional study to determine the association between OSA and CT calcium measures and 
determined whether COPD subtypes alter these relationships. 
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6.3. SUBJECTS AND METHODS 
6.3.1. Population 
COPDgene is a multicenter epidemiologic case-control study of 10,279 current 
and former smoking men and women, non-Hispanic White and African American 
between the ages of 45 and 80, with at least a 10 pack year history of smoking. The study 
was designed to study the genetic susceptibility to COPD. Subjects were recruited based 
on presence or absence of COPD as defined by post bronchodilator spirometry 
measurements (forced vital capacity; FVC < 0.70); ndd EasyOneTM spirometer (Zurich, 
Switzerland)  using standard protocol [167] and further characterized by severity using 
forced expiratory volume in one second percent predicted (FEV1pp) as defined by the 
Global Initiative for Obstructive Lung Disease (GOLD stage) criteria [163].  
In the full COPDgene cohort, only subjects who had complete data available were 
evaluated to assess the relationships between self-reported OSA and coronary 
calcification measures (n= 4494, CAC; n=4494, TAC). 
A single site sample of COPDGene subjects from National Jewish Health were 
recruited for an ancillary study collecting additional sleep data. Approval was obtained 
from the National Jewish Health Institutional Review Board and COPDGene executive 
committee to conduct the ancillary study. Four hundred and six subjects consented to be 
included in the study. Of those subjects, 98 were identified as having a previously 
conducted attended overnight polysomnogram (sleep study) conducted between 2008-
2012 at National Jewish Health using the computerized recording system (Embla, 
REMbrant version 9, Broomfield, CO, USA) Details from each sleep study were 
ascertained by electronic medical record chart review. All subjects were confirmed as 
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having a positive or negative OSA diagnosis through electronic medical chart review 
irrespective of whether or not the sleep study was conducted at National Jewish Health. 
For the single site analyses, only subjects with complete data were included in the 
analyses (n=179, CAC; n=179, TAC).  
6.3.2. Polysomnogram 
The polysomnogram consisted of continuous polygraphic recording from surface 
leads. Electroencephalography electrodes were applied at C4-A1, C3-A2, O1-A2, and 
O2-A1 to monitor brain waves. Chin muscle activity was measured by electromyography. 
Eye movements were identified by electrooculography. Oronasal airflow was monitored 
using both a thermocouple (thermistor) and pressure transducer. Thoracic and abdominal 
impedance belts were used to measure respiratory effort. Oxyhemoglobin saturation in 
the blood was measured through pulse oximetry. A tracheal microphone was used to 
monitor snoring. Sensors were placed on each leg to monitor leg movements as well as a 
sensor to monitor sleep position. Polysomnographic recordings were scored manually by 
trained polysomnographic technologists with sleep stages and arousals identified using 
standard criteria [171] and respiratory events scored in accordance with the American 
Academy of Sleep Medicine (AASM) [172].  
An apnea is defined as complete cessation of airflow for 10 seconds or more 
identified from the thermocouple (thermistor) channel, accompanied with an arousal 
and/or a ≥4% oxyhemoglobin desaturation identified on SpO2 channel. A hypopnea is 
defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% 
decrease in thoracoabdominal movement on thoracic/abdominal impedance belts or 
decrease in airflow identified on the pressure transducer channel as compared with 
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baselines and oxyhemoglobin desaturation of ≥4% or 50% decrease in thoracoabdominal 
movement or airflow, as compared with baseline with an associated arousal on EEG. 
OSA was defined as an AHI of ≥ 5 with severity classified by AASM [172] as 
follows: AHI ≥ 5 -14 (mild), an AHI ≥ 15-29 (moderate) and AHI ≥ 30 (severe). Other 
variables ascertained from medical records included the total continuous sleep time each 
subjects’ oxygen saturation remained below 88%, lowest oxygen saturation during the 
study and baseline oxygen saturation at sleep onset.  
Self-reported OSA was determined by a “yes” response to a series of questions: 
Have you ever been told you have sleep apnea and / or has a physician ever told you that 
you have sleep apnea? 
All subjects received CT scans using multi-detector CT scanners (at least 16 
detector channels). Volumetric CT acquisitions were obtained both on full inspiration 
(200 mAs), and at the end of normal expiration (50 mAs)[99]. Image reconstruction 
utilized sub-millimeter slice thickness, with smooth and edge-enhancing algorithms. The 
following analyses were performed on segmented lung images, using Slicer 
(www.Slicer.org): total inspiratory and expiratory lung volumes, and relative lung 
volumes falling below attenuation thresholds of −950, −910 and −856 HU. Measures of 
emphysema were reported using the -950HU threshold (%LAA-950) from the inspiratory 
scans with further meeting a threshold value of ≥5 percent emphysema of the total lung 
based on previous work from Zach and colleagues evaluating CT thresholds in non-
smoking controls [165].  
In defining COPD by function, cases were defined by post bronchodilator 
spirometry as GOLD stages 2-4 and smoking controls defined as GOLD stage 0. The 
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chronic bronchitis phenotype was defined by standard protocol as chronic productive 
cough for 3 months in each of 2 successive years in a patient of whom other 
causes of productive chronic cough have been excluded [166].  
All subjects received an ECG ungated coronary calcium scan using a GE 64-
detector Light Speed VCT machine (General Electric Medical Systems, Milwaukee, WI).  
Images were obtained at 2.5 mm intervals beginning one centimeter below the carina and 
progressing caudally to include all coronary arteries. Thoracic images were obtained in 
the helical mode, with a pitch of 1.375. The settings of the scanner were 120 kVp, 430 
mA, 500 ms/per rotation. Effective radiation dose using this technique was approximately 
1 mSv per patient, measured effective dose (ED) was calculated by multiplying the dose 
length product by the conversion factor for the chest (0.014). 
 Images were reconstructed as contiguous 2.5 mm slice thickness for measures of 
Coronary arterial calcium (CAC) and Thoracic arterial Calcium (TAC). TAC was defined 
as either ascending or descending thoracic aortic calcium, as present from the pulmonary 
artery bifurcation superiorly to the cardiac apex inferiorly. TAC of the un gated 
reconstructed images were measured using the same range as the gated scan, to allow 
more direct comparison of the measures.  
Both coronary and thoracic aortic calcium were classified using a CT threshold of 
130 Hounsfield units (HU) involving 3 contiguous voxels for identification of a calcific 
lesion resulting in a minimum lesion area of 1.02 mm2. The lesion score was calculated 
using the area density method summing lesion scores from the four major coronary 
arteries (left main, left anterior descending, left circumflex, and right coronary arteries) as 
described by Agatston [168]. 
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Smoking status was a created variable of current and former smokers using a 
modified questionnaire taken from the ATS adult respiratory questionnaire [169]. 
Subjects were classified as current smokers if they answered “Yes” to the following 
question: Do you now smoke cigarettes (as of a month ago)? Subjects who did not 
answer “Yes” to the aforementioned question were classified as former smokers. 
Pack-years were calculated using standard questions from the ATS Adult 
Respiratory Questionnaire. The average number of cigarettes smoked per day was 
divided by twenty to convert to packs.    
Age, gender, and race were ascertained from a demographic questionnaire. Body 
mass index was calculated by dividing weight in kilograms by meters squared (kg/m2). A 
medication questionnaire was used to identify all medications (brand name and generic) 
taken by each subject. Covariates such as high blood pressure and high cholesterol were 
defined by self-report as many medications which would have assisted with defining 
covariates are important to adjust for in multivariable models given our specific 
hypotheses. Diabetes was defined by self-reported diabetes and/or use of at least one 
diabetic medication.    
6.4. STATISTICAL METHODS 
All analysis were performed using the SAS system version 9.3 (Copyright (c) 
2002-2008 by SAS Institute Inc., Cary, NC, USA).  Means and standard deviations or 
medians and interquartile ranges are reported for all variables as appropriate with 
comparisons made using students ttest or wilcoxon sum ranked test for non-normally 
distributed data or small sample size. Multivariable logistic regression models of 
dichotomous coronary and thoracic calcium measures adjusting for covariates were 
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utilized and multinomial logistic used when the proportional odds assumption was 
violated. Kruskal Wallace test was used to assess trend of prevalent OSA across CAC 
and TAC categories.  
Criteria for covariate inclusion in the multivariable model was statistical 
significance of the covariate and outcome in univariable analysis at a p value of <0.10.  
All significant covariates were included in the full model and a manual backward 
stepwise approach was utilized. Each excluded variable was examined to see if it 
influenced the relationship between the exposure and outcome by changing the beta 
estimate of OSA by more than 10%. Covariates that changed the beta estimate by more 
than 10% were maintained in the model. Model fit was assessed using log likelihood for 
nested models or AIC for non-nested models.  
6.5. RESULTS 
6.5.1. Self-Reported OSA 
In the COPDGene cohort, 51% of population had CAC (Table 6.1.). Subjects with 
CAC are older, have greater accumulated pack years of smoking, as well as greater 
percentage of cardiovascular risk factors, higher prevalence of OSA, worse lung function, 
more emphysema with greater medication use compared to subjects without CAC. Across 
GOLD stages, there is a significant trend of prevalent self-reported OSA (p<0.0001, 
Jonckheere-Terpstra test for trend, Figure 6.1.).  
In the COPDGene cohort, 64% of population had TAC (Table 6.2.). Similar to 
what we saw in CAC, subjects with TAC are older, have greater accumulated pack years 
of smoking, as well as greater percentage of cardiovascular risk factors, and higher 
prevalence of OSA, worse lung function, and more emphysema compared to  
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OSA, n (% Yes) 310 (13.50) 189 (8.63) <0.0001 
Age, mean ± SD 62.79 ± 8.33 55.80 ± 7.88 <0.0001 
Gender ,n (%Male) 1245 (54.53) 948 (43.51) <0.0001 
Race, n (% Cauc) 1773 (77.66) 1311 (60.17) <0.0001 
BMI, mean± SD 28.60 ± 6.00 28.83 ± 6.39   0.2013 
Smoking, n (% Current) 1013 (44.37) 1276 (58.56) <0.0001 
Pack Years, mean ± SD 46.72 ± 24.44 38.30 ± 20.15 <0.0001 
Diabetes, n (% Yes) 334 (14.55) 189 (8.65) <0.0001 
COPD, n (% Yes) 994 (54.20) 553 (31.56) <0.0001 
Chronic Bronchitis 263 (17.79) 275 (15.68)   0.1077 
Total emphysema ≥ 5% 608 (33.35) 318 (17.70) <0.0001 
FEV1pp 73.66 ± 25.91 81.74 ± 23.25 <0.0001 
FVC 86.36 ± 18.32 89.41 ± 17.16 <0.0001 
FEV1/FVC 0.64 ± 0.16 0.71 ± 0.14 <0.0001 
High Blood Pressure 1079 (47.28) 666 (30.56) <0.0001 
High Cholesterol 961 (42.09) 624 (28.64) <0.0001 
Oxygen Use, n (%Yes) 281 (12.31) 139 (6.38) <0.0001 
Steroid Use, n (%Yes) 566 (24.66) 369 (16.90) <0.0001 
Statin Use, n (%Yes) 539 (23.33) 276 (12.57) <0.0001 
      COPD=Chronic Obstructive Pulmonary Disease; COPD defined as those in       
      GOLDstages 2-4; OSA=Obstructive Sleep Apnea;CAC=Coronary Arterial Calcium. 
 
 
    Figure 6.1. Prevalent Self-Reported OSA across CAC Categories 
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   Table 6.2. Characteristics of TAC  





OSA, n (% Yes) 369 (15.01) 128 (9.28) <0.0001 
Age, mean ± SD 62.01 ± 8.41 54.60 ± 7.47 <0.0001 
Gender, n (% Male) 1387 (48.23) 806 (50.82)   0.0973 
Race, n (% Cauc) 2152 (74.83) 9.32 (58.76) <0.0001 
BMI, mean ± SD 28.48 ± 5.96 29.14 ± 6.57 <0.01 
Smoking, n (% Current) 1310 (45.55) 979 (61.73) <0.0001 
Pack Years, mean ± SD 45.25 ± 23.81 37.81 ± 20.10 <0.0001 
Diabetes, n (% Yes) 387 (13.39) 136 (8.56) <0.0001 
COPD, n (% Yes) 1164 (29.73) 379 (50.87) <0.0001 
Chronic Bronchitis(%Yes) 318 (16.29) 220 (17.19)   0.5034 
Total emphysema ≥ 5% 697 (29.90) 229 (17.77) <0.0001 
FEV1pp, mean ± SD 74.75 ± 25.65 82.81 ± 22.80 <0.0001 
FVCpp, mean ± SD 86.66 ± 18.20 90.02 ± 16.90 <0.0001 
FEV1/FVC, mean ± SD 0.65 ± 0.16 0.71 ± 0.14 <0.0001 
High Blood Pressure, n (%Yes) 1271 (44.21) 474 (29.89) <0.0001 
High Cholesterol, n (%Yes) 1140 (39.64) 445 (28.06) <0.0001 
Oxygen Use, n (%Yes) 335 (11.65) 85 (5.36) <0.0001 
Steroid Use, n (%Yes) 688 (23.81) 247 (15.54) <0.0001 
Statin Use , n (%Yes) 620 (21.45) 192 (12.08) <0.0001 
              COPD=Chronic Obstructive Pulmonary Disease; COPD defined as those in GOLD        
              stages 2-4; OSA=Obstructive Sleep Apnea; TAC=Thoracic Arterial Calcium.   
 
 
      Figure 6.2. Prevalent Self-Reported OSA across TAC Categories 
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subjects without TAC. As there are no clinical guidelines for thoracic calcification TAC 
was analyzed in quartiles; quartile 0, mean 0 (range 0 – 0), quartile 1, mean 68 (range 1 – 
176), quartile 2, mean 402 (range 178 – 772), quartile 3, mean 3142(range 778 – 21120). 
There was a significant trend of decreased prevalent OSA with increasing TAC (p<0.05, 
Figure 6.2.). 
In the COPDGene cohort, 11% of subject’s self-reported physician diagnosed 
OSA (Table 6.3.). Subjects with OSA were older, former smokers with greater 
accumulated pack year history compared to subjects without self-reported OSA. These 
same subjects also weighed more and had a greater prevalence of chronic bronchitis and 
diabetes with worse pulmonary function.  
There was a significant relationship between self-reported OSA and CAC (Table 
6.4.) specifically within subjects with CAC, you have a 60% increased odds of reporting  
 







Age, mean ± SD 61.77 ± 8.69 59.25 ± 9.04 <0.0001 
Gender, n (% Male) 747 (60.10) 4703 (52.55) <0.0001 
Race, n (% Caucasian) 960 (77.23) 5824 (65.08) <0.0001 
BMI, mean ± SD 33.53 ± 7.27 28.15 ± 5.82 <0.0001 
Smoking,  n (% Current) 441 (35.48) 4973 (55.57) <0.01 
Pack Years, mean ± SD 49.20 ± 27.44 43.53 ± 43.02 <0.0001 
Emphysema, n (% Yes) 253 (27.59) 1963 (26.81) NS 
Chronic Bronchitis, n (% Yes) 208 (23.85) 1074 (16.70) <0.0001 
GOLD stages 2-4, n (% Yes) 557 (58.08) 3133 (44.01) <0.0001 
Diabetes, n (% Yes) 372 (29.93) 1025 (11.45) <0.0001 
High Blood Pressure, n (% Yes) 766 (61.67) 3629 (40.55) <0.001 
High Cholesterol, n (% Yes) 706 (56.80) 3794 (35.69) <0.0001 
FEV1pp, mean ± SD 70.30 ± 24.23 77.20 ± 25.62 <0.0001 
FVCpp, mean ± SD 80.93 ± 18.66 87.82 ± 18.14 <0.0001 
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OSA and this odds increases for the highest level of CAC (OR=1.66, 95% CI=1.08-2.56, 
p<0.05) in adjusted models. Similarly subjects with TAC are 57% more likely to report 
OSA. Interactions between OSA and emphysema were not significant (p=0.8372, data 
not shown) however there was an interaction between OSA and chronic bronchitis (p= 
0.0658). We were not able to further evaluate this interaction due to smaller cell sizes. 

















Model 1 adjusted for age at enrollment (p<0.0001), gender (p<0.0001), current smoking (p<0.001), 
emphysema (p<0.0001), high blood pressure (p<0.0001), and diabetes (p<0.05). *Proportional odds 
assumption not met therefore used multinomial logistic regression. CAC categories: a= 1-100, b= 
101-400, c= >400 compared to no CAC. FEV1pp included however did not improve model fit and 
did not confound the relationship so omitted. Emphysema OR=1.39, 95% CI=1.17-1.67, p<0.001. 
Model 2 adjusted for age at enrollment (p<0.0001), gender (p=0.2379), current smoking (p<0.01), 
emphysema (p=0.9226), high blood pressure (p<0.0001), FEV1pp (p<0.001). FEV1pp acts as a 
precision variable improving model fit so included in                                     
model. 
Variables  Multivariable  
OR 
95% CI p value Ordinal  
OR 
95% CI p value 




































6.5.2. Physician Diagnosed OSA 
Subjects with CAC were older with greater number of accumulated pack years of 
smoking, worse lung function, greater percentage of emphysema, and more hypertension 
(Table 6.5.) compared to subjects without CAC. When CAC was categorized using 
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OSA, n (% Yes) 39 (29.10) 21 (22.11) 0.2353 
Age, mean ± SD 64.36 ± 7.66 58.97 ± 8.07 <0.0001 
Gender, n (% Male) 51 (54.84) 18 (21.18) <0.0001 
Race, n (% Caucasian) 91 (97.85) 83 (97.65) 0.9275 
BMI, mean ± SD 28.42 ± 5.59 27.91 ± 5.76 0.5492 
Smoking,  n (% Current) 18 (19.35) 25 (29.41) 0.1174 
Pack Years, mean ± SD 50.41 ± 26.96 37.14 ± 32.32 <0.001 
Diabetes, n (% Yes) 13 (13.98) 7 (8.24) 0.2255 
GOLD stage 2-4, n (% Yes) 59 (72.84) 28 (41.18) <0.0001 
Emphysema, n (%Yes) 49 (52.69) 27 (31.76) <0.01 
Chronic Bronchitis, n (% Yes) 19 (20.43) 17 (20.00) 0.9431 
FEV1pp, mean ± SD 64.84 ± 27.43 80.39 ± 27.08 <0.001 
FVCpp, mean ± SD 85.39 ± 17.18 94.24 ± 16.59 <0.001 
FEV1pp/FVC, mean ± SD  0.56 ± 0.18 0.65 ± 0.17 <0.01 
Hypertension, n (% Yes) 41 (44.09) 20 (23.53) <0.01 
High Cholesterol, n (% Yes) 43 (46.24) 32 (37.65) 0.2464 
Statin_use, n (%Yes) 20 (21.51) 14 (16.47) 0.3934 
Steroid_use, n (%Yes) 35 (37.63) 27 (31.76) 0.4116 
                Figure 6.3.  Prevalent Obstructive Sleep Apnea by Categories of CAC 
                Jonckheere-Terpstra test for trend p <0.05 
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had increased OSA prevalence (21.4% for CAC 1-100 and 40.6% for CAC 101-400)  
(Figure 6.3.) and there was a significant trend in OSA prevalence by increasing CAC 
severity (Figure 6.3., p<0.05, for trend). 
Subjects with TAC were older with greater number of accumulated pack years of 
smoking, higher frequency of diabetes, more COPD specifically greater percentage of 
emphysema, (Table 6.6.) reduced pulmonary function, and greater percentage of 
hypertension compared to subjects without TAC. 
As there are no clinical guidelines for thoracic calcification, TAC was analyzed in 
quartiles; quartile 0, mean 0 (range 0 – 0), quartile 1, mean 61 (range 4 – 176), quartile 2,  
 






OSA, n (% Yes) 45 (27.27) 15 (23.44) 0.5537 
Age, mean ± SD 63.78 ± 7.56 57.45 ± 8.22 <0.0001 
Gender, n (% Male) 56 (49.90) 13 (23.21) <0.01 
Race, n (% Caucasian) 120 (98.36) 54 (96.43)   0.4193 
BMI, mean ± SD 28.15 ± 5.39 28.25 ± 6.27   0.9180 
Smoking,  n (% Current) 23 (18.85) 20 (35.71) <0.05 
Pack Years, mean ± SD 47.60 ± 25.34 36.38 ± 31.46 <0.01 
Diabetes, n (% Yes) 12 (9.84) 8 (14.29)   0.3827 
GOLD stage 2-4, n (% Yes) 71 (70.30) 16 (33.33) <0.0001 
Emphysema, n (%Yes) 61 (50.00) 15 (26.79) <0.01 
Chronic Bronchitis, n (% Yes) 24 (19.67) 12 (21.43)   0.7865 
FEV1pp, mean ± SD 66.96 ± 28.28 83.84 ± 24.82 <0.001 
FVCpp, mean ± SD 87.12  ± 17.74 95.09 ± 15.52 <0.01 
FEV1pp/FVC, mean ± SD  0.57 ± 0.15 0.68 ± 0.18 <0.001 
Hypertension, n (% Yes) 50 (40.98) 11 (19.64) <0.01 
High Cholesterol, n (% Yes) 51 (41.80) 24 (42.86)   0.8948 
Statin_use, n (%Yes) 22 (18.03) 12 (21.43)   0.5925 
Steroid_use, n (%Yes) 49 (40.16) 13 (23.21) <0.05 
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mean 706 (range 178 – 1386), quartile 3, mean 2431(range 1765 – 3636). There was not a 
significant trend of prevalent OSA with increasing TAC (p=0.3214) however those with 
higher levels of TAC had increased prevalence (32.3% for quartile 1, 24.4 for quartile 2, 
Figure 6.4.).      
 
In the single site cohort, 24% of subjects had physician diagnosed OSA by 
polysomnography (Table 6.7.). Subjects with OSA weighed more, more likely to be 
former smokers with greater percentage of chronic bronchitis and diabetes with less 
emphysema compared to subjects without self-reported OSA. These same subjects also 
weighed more and had a greater prevalence of chronic bronchitis and reduction in 
FEV1pp. 
Physician diagnosed OSA was associated with any CAC adjusting for age at 
enrollment, gender, current smoking, emphysema, hypertension, and diabetes (OR=3.65, 
95% CI 1.02-13.09, p<0.05, Table 6.8.).  
  
 
 Figure 6.4.  Prevalent Obstructive Sleep Apnea by Categories of TAC 
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   Table 6.8.  Relationship between Physician Diagnosed OSA and Calcification   






   
 
    Model 1 adjusted for age at enrollment (p<0.01), gender (p<0.05), current smoking        
    (p=0.5222), emphysema (p<0.05), high blood pressure (p=0.2831), and diabetes      
    (p=0.1918) *FEV1pp did not confound the relationship or improve model fit so      
    omitted. Current smoking, high blood pressure, and diabetes were not significant  
    however, confounded the relationship by more than 10% so included in model.   
    Model 2 adjusted for age at enrollment (p<0.001), gender (p=0.2097), emphysema   
    (p<0.01), and high blood pressure (0.1302). High blood pressure not significant  
    however confounded the relationship by more than 10% so left in model. * FEV1pp      
    did not confound the relationship or improve model fit so omitted. 
 
Variables  Multivariable 
OR 





















Age, mean ± SD 63.53 ± 8.58 63.02 ± 8.62 NS 
Gender, n (% Male) 54 (55.10) 143 (45.15) NS 
Race, n (% Caucasian) 94 (95.92) 275 (95.59) NS 
BMI, mean ± SD 33.66 ± 7.39 27.39 ± 4.71 <0.0001 
Smoking,  n (% Current) 15 (15.31) 90 (30.30) <0.01 
Pack Years, mean ± SD 50.97 ± 26.00 45.98 ± 26.35 NS 
Emphysema, n (% Yes) 30 (30.61) 128 (43.10) <0.05 
Chronic Bronchitis, n (% Yes) 31 (31.63) 55 (18.52) <0.01 
GOLD stages 2-4, n (% Yes) 48 (63.16) 146 (60.58) NS 
Diabetes, n (% Yes) 27 (27.55) 32 (10.77) <0.0001 
High Blood Pressure, n (% Yes) 59 (60.20) 118 (39.73) <0.001 
FEV1pp, mean ± SD 69.04 ± 21.31 71.10 ± 67.96 NS 
FVCpp, mean ± SD 81.64 ± 17.48 88.55 ± 17.51 <0.001 
FEV1pp/FVC, mean ± SD 0.64 ± 0.13 0.60 ± 0.18 NS 
FRC, mean ± SD 3.11 ± 1.03 3.32 ± 1.23 NS 
TLC, mean ± SD 5.65 ± 1.43 6.08 ± 1.46 <0.05 
 
 
                                                                                            90 
 
Interactions between OSA and Emphysema were not significant (p=0.5624, data not 
shown) however there was an interaction between OSA and Chronic bronchitis (p= 
0.0170).  
Within individuals with coronary calcification, OSA was not related to worsened 
calcium measures as defined by CAC categories (p=0.1739 for each higher CAC 
category) in multivariable models (data not shown). When assessing the relationship 
between OSA and TAC there was no association (OR=3.28, 95% CI 0.82-13.15, 
p=0.0933, Table 6.8.).  
Given the hypoxic mediated inflammation hypothesis leading to atherosclerosis, 
we evaluated correlations between OSA severity, oxygenation measures collected from 
the sleep studies and calcium measures. We saw a significant correlation between time in 
minutes below SpO2 88% and calcification measures although there was a greater 
correlation of this measure and TAC (Table 6.9.).  
 
     Table 6.9. Correlation Matrix of Associations between Sleep Study Measures and       










    
 




     Results from Spearman rank correlation 
 CAC TAC 
AHI r = 0.27 
p=0.1879 
n=26 
r = 0.11 
p=0.5823 
n=26 
Low O2 Sleep Study r = -0.39 
p=0.04 
n=27 
r = -0.34 
p=0.0825 
n=27 
SpO2 <88% minutes r = 0.42 
p=0.04 
n=24 
r = 0.60 
0.0019 
n=24 
Baseline SpO2 at sleep 
onset 
r = -0.38 
p=0.3600  
n=8 
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6.6. DISCUSSION 
Our study demonstrated that OSA was associated with CAC independent of 
Emphysema and adjusting for age, gender, current smoking, diabetes, and high blood 
pressure when using both self-reported OSA and physician sleep study diagnosed OSA. 
However, when using self-reported OSA, our results were ameliorated (OR=1.60 for self-
report compared to OR= 3.65 for sleep study diagnosed, respectively).  This is not 
surprising given our previous research showing that OSA by self-report had a moderate 
sensitivity to accurately identify subjects with OSA (64.3%, unpublished data) as many 
subjects reported no OSA when they actually have OSA (false negatives) which in fact 
would bias our results toward the null ameliorating our risk estimate.  
Our study also found that there was an association between self-reported OSA and 
TAC however, although we saw a similar risk estimate change in sleep study diagnosed 
OSA and TAC compared to self-reported OSA and TAC, the result was not statistically 
significant. A limitation to this result was thought to be the result of smaller sample size 
however, power analysis suggests that a sample size of n=57 was needed to see the same 
effect.  
We also found that there was a significant trend in OSA prevalence by increasing 
CAC categories although prevalence of self-reported OSA was considerably smaller than 
prevalence of physician diagnosed OSA by CAC categories. Again, this could very well 
be the result of misclassification noted from our prior analyses.  
A limitation to our study is the cross sectional nature of our analysis which 
precludes our ability to determine causality however, we were able to show that there is 
an independent relationship between OSA and coronary calcification measures 
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independent of emphysema. Additionally, we were able to determine that pulmonary 
function and chronic bronchitis are not independently related to coronary calcification 
although when combined with OSA, we did see an interaction between OSA and chronic 
bronchitis (p=0.04) which was not seen in OSA and emphysema or OSA and GOLD 
stages 2-4. This is extremely important as this is the first study to look at the interaction 
of OSA and COPD specifically evaluating OSA and varying subtypes.  
The longitudinal follow-up in the COPDGene cohort will give us the ability to 
evaluate temporality of OSA and coronary calcium independently and in the presence of 
COPD as we have a diverse population of subjects that fall into various categories of 
COPD subtypes with and without functional limitation.  
In conclusion, there is an independent relationship between OSA and CAC. This 
study is the first to examine the relationship between OSA and CAC specifically testing 
the relationship between OSA and different COPD subtypes and how they affect this 
relationship. It is important to consider COPD subtypes with OSA as Overlap syndrome 
has been shown to increase CVD mortality and understanding these relationships and 
how they affect CVD outcomes will assist physicians with determining subjects at 
greatest risk for subclinical atherosclerosis.
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CHAPTER VII 
PILOT STUDY DEVELOPING NEW OXYGENATION VARIABLE FROM 
POLYSOMNOGRAM 
7.1. ABSTRACT  
Obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease 
(COPD) or Overlap Syndrome [10] affects approximately 1% of the population [11-12] 
and has been shown to increase cardiovascular disease (CVD) mortality [13]. CVD, 
specifically atherosclerosis is said to be caused by hypoxic mediated inflammation in 
OSA [12] and COPD [12] although this is likely due to the re-saturation phase as 
opposed to de-saturation phase [39-43].  
The aim of this study was to develop a novel variable capturing the re-saturation 
phase from the Spo2 channel of a polysomnogram and examine differences in re-
saturation time between subjects with OSA alone and subjects with OSA and different 
COPD phenotypes and further evaluate the association of this variable with calcification 
measures. A small convenience sample of subjects with available polysomnographic 
records were recruited for a single site study from the larger COPDgene cohort. 
Subjects with OSA and emphysema had significantly greater re-saturation time 
than subjects with OSA alone and there was a significant increasing trend of re-saturation 
time in subjects with OSA and emphysema by GOLD stage.  
 In conclusion, this is the first study evaluating re-saturation differences in 
subjects with OSA and OSA with concurrent emphysema or chronic bronchitis by 
creation of a novel variable collected with existing polysomnograhic data. This variable 
has great potential for future use in evaluating the hypoxic pathway leading to CVD.  
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7.2. INTRODUCTION 
Approximately 84 million individuals in the United States have cardiovascular 
disease (CVD) and it is the leading cause of death averaging one death every forty 
seconds [25].  
Obstructive sleep apnea (OSA) is characterized by repeated episodes of upper 
airway collapse during sleep with associated oxygen desaturations and sleep 
fragmentation affecting an estimated 3-7% of adults in the general population [2] and is 
related to incident CVD. The Sleep Heart Health study found that men with severe OSA 
(AHI of >30) had increased risk for incident heart failure and coronary heart disease 
(CHD: heart attack, CHD death, or coronary revascularization procedure) and this risk 
increased by OSA severity [3]. COPD has become the third leading cause of death behind 
CVD and cancer [4] affecting between 10 and 20 million adults [5]. Several studies have 
demonstrated that an obstructive pattern on spirometry is an independent risk factor for 
myocardial infarction, cardiovascular mortality, and stroke [6-9] in samples of the 
general population.  
In 1985, Flenley identified the concurrence of OSA and COPD and devised the 
name Overlap Syndrome (OS) [10] to describe the condition. Today, prevalence has been 
documented to occur anywhere from 1% in population studies [11-12] to 40% in clinical 
studies [13] and has been shown to increase the risk for cardiovascular disease mortality 
[13].  
Specifically, atherosclerosis development in OSA and COPD have been 
hypothesized to be caused by inflammatory pathway signaling mediated by hypoxia [12] 
and subjects with Overlap syndrome are at greater risk of prolonged oxygen desaturation 
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at night than those with OSA alone and degree of airflow obstruction, as measured by 
FEV1/FVC, correlates with risk of prolonged hypoxemia [14]. However, a direct 
relationship between existing oxygenation measures found on a standard polysomnogram 
(desaturation index, baseline SpO2) have shown lack of association with coronary 
calcium measures in adjusted models [113] but studies comparing phases of oxygenation: 
re-perfusion vs. de-saturation have shown that cardiovascular damage results from the re-
perfusion phase rather than de-saturation itself as shown by production of reactive 
oxygen species (ROS) [39-43]. Despite these results, no one has developed a re-
saturation variable using polysomnographic recordings done on human subjects with 
further testing of differences in re-saturation between OSA and COPD subjects with 
further testing of associations between re-saturation and calcification measures.     
The first aim of this study was to develop a novel measure of re-saturation and 
examine differences in this measure between subjects with OSA compared to different 
overlap categories.   
Next, we will examine the relationship between this measure and coronary 
calcification measures and determine whether this measure has better correlation with 
calcification measures than current measures of oxygenation derived from a standard 
polysomnogram.   
7.3. SUBJECTS AND METHODS 
7.3.1. Population 
COPDgene is a multicenter epidemiologic case-control study of 10,192 current 
and former smoking men and women, non-Hispanic White and African American 
between the ages of 45 and 80, with at least a 10 pack year history of smoking. The study 
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was designed to study the genetic susceptibility to COPD. Subjects were recruited based 
on presence or absence of COPD as defined by post bronchodilator spirometry 
measurements (forced vital capacity; FVC < 0.70); ndd EasyOneTM spirometer (Zurich, 
Switzerland)  using standard protocol [167] and further characterized by severity using 
forced expiratory volume in one second percent predicted (FEV1pp) as defined by the 
Global Initiative for Obstructive Lung Disease (GOLD stage) criteria [163].  
A single site sample of COPDGene subjects from National Jewish Health were 
recruited for an ancillary study collecting additional sleep data from electronic medical 
chart review. Approval was obtained from the National Jewish Health Institutional 
Review Board and COPDGene executive committee to conduct the ancillary study.  
Four hundred and six subjects consented to be included in the study with 98 
identified as having a previously conducted attended overnight polysomnogram (sleep study) 
conducted between 2008-2012 at National Jewish Health using the computerized recording 
system (Embla, REMbrant version 9, Broomfield, CO, USA) Details from each sleep study were 
ascertained by electronic medical record chart review. Of the 98 subjects with sleep studies 
conducted at National Jewish Health, n=16 met the criteria for inclusion in the study: sleep study 
conducted pre-treatment and full sleep study record).  
7.3.2. Polysomnogram 
The polysomnogram consisted of continuous polygraphic recording from surface 
leads. Electroencephalography electrodes were applied at C4-A1, C3-A2, O1-A2, and 
O2-A1 to monitor brain waves. Chin muscle activity was measured by electromyography. 
Eye movements were identified by electrooculography. Oronasal airflow was monitored 
using both a thermocouple (thermistor) and pressure transducer. Thoracic and abdominal 
impedance belts were used to measure respiratory effort. Oxyhemoglobin saturation in 
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the blood was measured through pulse oximetry. A tracheal microphone was used to 
monitor snoring. Sensors were placed on each leg to monitor leg movements as well as a 
sensor to monitor sleep position. Polysomnographic recordings were scored manually by 
trained polysomnographic technologists with sleep stages and arousals identified using 
standard criteria [171] and respiratory events scored in accordance with the American 
Academy of Sleep Medicine (AASM) [172].  
An apnea was defined as complete cessation of airflow for 10 seconds or more 
identified from the thermocouple (thermistor) channel, accompanied with an arousal 
and/or a ≥4% oxyhemoglobin desaturation identified on SpO2 channel. A hypopnea is 
defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% 
decrease in thoracoabdominal movement on thoracic/abdominal impedance belts or 
decrease in airflow identified on the pressure transducer channel as compared with 
baseline and oxyhemoglobin desaturation of ≥4% or 50% decrease in thoracoabdominal 
movement or airflow, as compared with baseline with an associated arousal on EEG. 
OSA was defined as an AHI of ≥ 5 with severity classified by AASM [172] as 
follows: AHI ≥ 5 -14 (mild), an AHI ≥ 15-29(moderate) and AHI ≥ 30 (severe). Other 
variables ascertained from medical records included the total continuous sleep time each 
subjects’ oxygen saturation remained below 88%, lowest oxygen saturation during the 
study and baseline oxygen saturation at sleep onset.  
7.3.3. Novel Variable: Re-saturation 
Using the digital recording of the SpO2 channel of the polysomnogram, we 
created a variable capturing re-saturation time for each subject that had available sleep 
study recordings. Previous studies have postulated that intermittent hypoxia is analogous 
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to ischemia-reperfusion injury where damage occurs when blood flow to a hypoxic tissue 
is restored [39-43] more specifically, damage from hypoxia is from the re-saturation 
phase rather than the de-saturation phase as shown by an increase in reactive oxygen 
species (ROS) production. 
This variable was ascertained pre-treatment (no positive airway pressure, oral 
appliances or oxygen therapy). We examined each qualifying polysomnogram in its 
entirety randomly selecting nine different events (apneas and hypopneas) and 
corresponding desaturations in stages 1, 2 and REM sleep.   
Re-saturation was defined by the amount of time in seconds it took for a subject 
to re-saturate after an apneic or hypopneic event. This was done by counting seconds 
from lowest de-saturation to the return to baseline for that subject (Figure 7.1.). Baseline 
was defined as SpO2 preceding each event. We were blinded to COPD type during 
collection of the re-saturation variable.  
COPD, specifically the emphysema type has reduced surface area available for 
gas exchange as shown by a reduction of the diffusing capacity of carbon monoxide 
(DLCO) [64] which we anticipated as presence on polysomnogram as longer time interval 
from peak desaturation to re-saturation to baseline on the Spo2 channel versus a subject 
with only OSA who would have normal surface area for gas exchange therefore shorter 
interval from peak desaturation to re-saturation to baseline on the SpO2 channel. 
Consideration of decreases in pulmonary function were also examined for effect on re-
saturation in the various overlap categories.  
In assessing re-perfusion, it was also important to consider subjects with diabetes 
type II as HbA1c is increased in diabetic subjects [178-180] and there is 10X the  
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affinity of oxygen to glycosylated hemoglobin compared to non-glycosylated hemoglobin 
[181] which could impact the re-saturation curve. Given the increased prevalence of type 
diabetes in OSA [149-150, 153 ], it is important for us to consider the possible effect 
diabetes may have on the re-saturation time as subjects with OSA and diabetes may have 
comparable re-saturation times as those in a chronic hypoxic state such as COPD which 
could lead to a bias in our results.  
Two additional variables; anemia and heart failure were identified as variables 
which could bias out results.  In anemic patients, the reduction of oxygen carrying 
capacity of the blood may lead to tissue hypoxia and elevated 2,3 DPG levels [62] thus 
creating a curve on re-saturation similar to COPD, biasing our results. Heart failure 
patients have been found to have high levels of 2, 3 DPG levels reducing the affinity of 
oxygen to hemoglobin in the lungs [63].  
7.3.4. Pulmonary Abnormalities 
All subjects received CT scans using multi-detector CT scanners (at least 16 
detector channels).  Volumetric CT acquisitions were obtained both on full inspiration 
   
    Figure 7.1. Method for Creating Re-saturation Variable from Polysomnogram       
    Figure adapted from: A. Avidan [176]. 
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(200 mAs), and at the end of normal expiration (50 mAs) [164]. Image reconstruction 
utilized sub-millimeter slice thickness, with smooth and edge-enhancing algorithms. The 
following analyses were performed on segmented lung images, using Slicer 
(www.Slicer.org): total inspiratory and expiratory lung volumes, and relative lung 
volumes falling below attenuation thresholds of −950, −910 and −856 HU. Measures of 
emphysema were reported using the -950HU threshold (%LAA-950) from the inspiratory 
scans with further meeting a threshold value of ≥5 percent emphysema of the total lung 
based on previous work from Zach and colleagues evaluating CT thresholds in non-
smoking controls [165].  
In defining COPD by function, cases were defined by post bronchodilator 
spirometry as GOLD stages 2-4 and smoking controls defined as GOLD stage 0. The 
chronic bronchitis subtype was defined by standard protocol as chronic productive cough 
for 3 months in each of 2 successive years in a patient of whom other causes of 
productive chronic cough have been excluded [166].  
7.3.5. Calcification Measures 
All subjects received an ECG ungated coronary calcium scan using a GE 64-
detector Light Speed VCT machine (General Electric Medical Systems, Milwaukee, WI).  
Images were obtained at 2.5 mm intervals beginning one centimeter below the carina and 
progressing caudally to include all coronary arteries. Thoracic images were obtained in 
the helical mode, with a pitch of 1.375. The settings of the scanner were 120 kVp, 430 
mA, 500 ms/per rotation. Effective radiation dose using this technique was approximately 
1 mSv per patient, measured effective dose (ED) was calculated by multiplying the dose 
length product by the conversion factor for the chest (0.014). 
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Images were reconstructed as contiguous 2.5 mm slice thickness for measures of 
Coronary arterial calcium (CAC) and Thoracic arterial Calcium (TAC). TAC was defined 
as either ascending or descending thoracic aortic calcium, as present from the pulmonary 
artery bifurcation superiorly to the cardiac apex inferiorly. TAC of the ungated 
reconstructed images were measured using the same range as the gated scan, to allow 
more direct comparison of the measures.  
Both coronary and thoracic aortic calcium were classified using a CT threshold of 
130 Hounsfield units (HU) involving 3 contiguous voxels for identification of a calcific 
lesion resulting in a minimum lesion area of 1.02 mm2. The lesion score was calculated 
using the area density method summing lesion scores from the four major coronary 
arteries (left main, left anterior descending, left circumflex, and right coronary arteries) as 
described by Agatston [168]. 
7.3.6. Other Covariates 
Smoking status was a created variable of current and former smokers using a 
modified questionnaire taken from the ATS adult respiratory questionnaire [169]. 
Subjects were classified as current smokers if they answered “Yes” to the following 
question: Do you now smoke cigarettes (as of a month ago)? Subjects who did not 
answer “Yes” to the aforementioned question were classified as former smokers. 
Pack-years were calculated using standard questions from the ATS Adult 
Respiratory Questionnaire. The average number of cigarettes smoked per day was 
divided by twenty to convert to packs.    
Age, gender, and race were ascertained from a demographic questionnaire. Body 
mass index was calculated by dividing weight in kilograms by meters squared (kg/m2). A 
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medication questionnaire was used to identify all medications (brand name and generic) 
taken by each subject. Covariates such as high blood pressure and high cholesterol were 
defined by self-report as many medications which would have assisted with defining 
covariates are important to adjust for in multivariable models given our specific 
hypotheses. Diabetes was defined by self-reported diabetes and/or use of at least one 
diabetic medication. 
7.4. STATISTICAL METHODS 
All analysis were performed using the SAS system version 9.3 (Copyright (c) 
2002-2008 by SAS Institute Inc., Cary, NC, USA).  Medians and interquartile ranges are 
reported for all continuous variables with comparisons made using Wilcoxon sum ranked 
test and categorical comparisons made using Fishers exact test for small sample sizes. 
Correlations between measures were assessed using Spearman rank correlation.  
Variability of the measure within each subject was tested using repeated measures 
ANOVA and Wilcoxon sum ranked test used to test differences between groups 
identified a priori. Fisher’s exact test was used to evaluate categorical variables. 
7.5. RESULTS 
Subjects with OSA and concurrent Emphysema were older and weighed 
less than subjects with only OSA (Table 7.1.). Occurrence of diabetes was not different 
between groups. FRC was greater in subjects with OSA and Emphysema. One subject in 
the OSA group was identified as anemic.  
The re-saturation time was not different within subjects across all events 
(p=0.3135) and these results remained despite event type or stage of sleep. After omitting 
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the subject with identified anemia, we compared re-saturation times by Overlap 
syndrome categories (Figure 7.2.). 
Subjects with CT emphysema had the greatest re-saturation time; (18.85 seconds, 
IQR 16.60-23.05), followed by subjects with OSA (13.75 seconds, IQR 12.50-14.90) and 
chronic bronchitis (12.75 seconds, IQR 12.10-18.70) respectively. Omitting the subject 
with anemia improved the variance explained by our model from an r square of 0.63 to 
0.71. Specifically comparing the difference in median re-saturation times between 
subjects with OSA and emphysema compared to subjects with only OSA yielded a 
statistically significant result (p=0.02, Figure 7.2.). Further evaluating whether 
pulmonary function could influence the results we examined the trend of median re-
saturation time across GOLD stages (data not shown).   
There was a significant difference in OSA/Emphysema from GOLD stage 
2 to 3 (p<0.0001, data not shown). Although there appeared to be a possible trend in re-
saturation time for subjects with OSA/chronic bronchitis across GOLD stages, this did 
not reach statistical significance (p=0.1652, data not shown). There was not a significant 
trend in OSA subjects from GOLD stage 0 to 3 (p=0.2956, data not shown). 
7.6. DISCUSSION 
In the preliminary results from our pilot study, we were the first to develop and 
document that re-saturation time does not vary within subjects despite differences in 
events and sleep stages.  Secondly, we were able to show that within OSA, subjects with 
concurrent emphysema have a much slower re-saturation time as compared with OSA 
alone (p=0.02). Comparing subjects with OSA alone and OSA with chronic bronchitis, 
re-saturation times were very similar (Figure 7.2). The results were not surprising as 
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subjects with emphysema have destruction of alveoli leading to reduction in diffusion 
capacity of the lungs [64] which we hypothesized to result in slower re-saturation times 
in subjects with both OSA and emphysema.  
             Figure 7.2 Distribution of Re-saturation Time by Overlap Categories 
Additionally, there appeared to be a possible trend in greater re-saturation times by 
GOLD stage in subjects with both COPD types (data not shown) which was not apparent 
in OSA subjects. This could be explained by factors favoring right shifts of the oxygen 
dissociation curve (ODC). Three factors can cause a right shift of the ODC thus reducing 
the loading of oxygen in the lungs and enhance release of oxygen to the tissues yielding 
lower oxygen saturation (SaO2) for any given PO2. We considered two of the three 
factors. 
One factor, 2,3 diphosphoglycerate (2,3-DPG) blood concentration influences the 
ODC under the effect of hypoxia and has been shown to be increased in subjects with 
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daytime hypoxemia [60] however intermittent hypoxia at night alone as in OSA is not 
enough to increase levels of 2,3 DPG [59]. Elevated levels of 2,3-DPG have been 
documented in patients with heart failure [63] which was not identified in our sample. 
Increase in 2,3-DPG have been documented in patients with chronic anemia [62]. We 
identified one subject with anemia in the OSA only group. Examining differences of 
median re-saturation between OSA only and OSA and concurrent emphysema changed 
by 1 second after omitting the anemic subject and improved the variance explained by 
our model from an r square of 0.63 to 0.71.  
A second factor favoring a right shift in the ODC is decrease in pH. Decrease in 
pH results from hypoventilation or ventilation/perfusion mismatching in COPD subjects 
causing subsequent rise in CO2 [64, 35-36] which is possible in subjects worse functional 
measures.  
This is a very important study as prevalence of OSA and COPD have been shown 
to increase CVD mortality [13]. Hypoxemia from both conditions impacts atherosclerotic 
development through inflammation [12] specifically inflammatory damage resulting from 
the re-saturation phase of hypoxemia [39-43] and the physiologic Spo2 signal from a 
polysomnogram offers a simple way to measure re-saturation in this population and could 
easily be programmed and offered as a summary measure in polysomnographic report. 
This information could assist physicians with identifying subjects at risk for developing 
subclinical atherosclerosis and tailor treatment accordingly.  
This study is not without limitations. First, the study was only done in a small 
convenience sample from a single site of the larger COPDGene cohort with existing 
polysomnographic records available at National Jewish Health. Due to the small sample, 
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we were not able to conduct statistical modeling adjusting for possible confounding 
variables. However, we did take a look at the distribution of variables between the 
different Overlap groups to assess possible influence of variables on the results. One 
subject with anemia was identified in our OSA only group and after omission, improved 
the variance explained in the model as well as increased the difference in re-saturation 
between the OSA only group and OSA/emphysema group by 1 second. Additionally, 
despite the small sample size we still found a statistically significant difference between 
median re-saturation time between subjects with OSA and emphysema compared to 
subjects with only OSA (p=0.02).  
In conclusion, this is the first study evaluating re-saturation differences in subjects 
with OSA and OSA with concurrent emphysema or chronic bronchitis by creation of a 
novel variable collected with existing polysomnograhic data. This variable has great 
potential for future use in further evaluating the hypoxic pathway leading to 
atherosclerotic CVD.  Further studies in larger populations are needed to validate the 
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CHAPTER VIII 
DISCUSSION AND FUTURE DIRECTIONS 
The prevalence of Overlap syndrome or concurrence of OSA and COPD has been 
shown to occur in 1% of the population. Overlap syndrome has been said to be strictly an 
epidemiologic phenomenon where there is a high prevalence of both OSA and COPD 
therefore individuals in the population will have both conditions. Studies have attempted 
to evaluate the relationship between OSA and COPD with contradictory results. These 
studies were limited by evaluating OSA in mild COPD and defining COPD by 
pulmonary function measures. COPD is a heterogeneous disease whose clinical, 
functional, and radiological presentation varies from patient to patient despite similar 
degree of airflow limitation and can encompass emphysema and chronic bronchitis 
independently or in conjunction.  
Presence of Overlap syndrome has been shown to increase the risk for 
cardiovascular disease mortality [13]. Specifically, atherosclerosis has been hypothesized 
to occur through hypoxic mediated inflammation with Overlap syndrome subjects having 
been shown to be at greater risk of prolonged oxygen desaturation at night than those 
with OSA alone.  However studies to date have shown lack of direct relationship between 
existing oxygenation measures found on a standard polysomnogram (desaturation index, 
baseline SpO2) with coronary calcium measures in adjusted models.  
It is important to evaluate the relationship between OSA and COPD by evaluating 
the individual pulmonary abnormalities to fully understand the complexities of this 
relationship and involvement in subclinical atherosclerosis. This was the first study to 
examine the relationship between OSA and different pulmonary abnormalities and further 
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determine the effects these abnormalities have on the relationship between OSA and 
subclinical atherosclerosis.  
8.1. VALIDITY OF SELF-REPORTED OSA AND BERLIN SLEEP 
QUESTIONNAIRE 
The first goal of this study was to examine the validity of our self-reported 
measure of OSA in the COPDGene cohort by comparing the self-reported measure to the 
gold standard (sleep studies) obtained from our ancillary study. Understanding 
measurement characteristics is an important methodological step for assessing the 
validity of risk estimates in an epidemiologic study.  Overall, self-reported OSA had 
moderate ability to accurately identify OSA and good ability to accurately identify 
subjects without OSA (Sensitivity, 64.3%; Specificity, 82.8%). The moderate sensitivity 
could be a reflection of the number of false negatives (subjects answering “no” to having 
OSA when they actually have OSA) noted in the study (Appendix C). Further exploring 
differences in sensitivity and specificity by COPD case status, resulted in a small 
reduction in sensitivity (62.5%) in subjects with COPD and improved specificity (88.4%) 
in subjects without COPD (Appendix C). Differential misclassification was present by 
COPD case status (22% of COPD cases and 17% of controls were misclassified).  
One explanation considered was whether the misclassification was the result of 
treatment. Were false negative subjects answering “no” because they were currently on 
treatment and conversely were false positive subjects answering “yes” to having OSA 
due to treatment prescribed as a result of a sleep study with a differential diagnosis (eg; 
low oxygen from COPD but without OSA). Examining the false negatives, we found that 
only one subject indicated that they were on treatment however within the false positive 
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subjects in our study, 30 (59%) of them indicated they were on treatment with 18 (60%) 
of them on nocturnal oxygen therapy however none of the misclassified subjects were on 
positive airway pressure therapy.  In addition, 12 of the 18 (67%) subjects had COPD 
(GOLD stages 2-4).  
Next, we examined the utility of the Berlin sleep questionnaire to identify OSA in 
our population. This provided valuable information regarding the validity of risk 
estimations in studies that used the Berlin Sleep Questionnaire as an assessment for OSA. 
Additionally, this is the first study assessing measurement characteristics of the Berlin 
sleep questionnaire in individuals with COPD. Overall, the Berlin questionnaire had poor 
ability to identify subjects with OSA in the entire cohort (42.1%) with further reduction 
of sensitivity within COPD subjects (34.5%, Chapter 4; Table 4.3. and Appendix B). 
Upon further evaluation we found that specifically subjects with COPD had a greater 
percentage of subjects giving positive responses to snoring frequency and feeling 
fatigue/sleepy during the day. These results were different in non COPD subjects where 
the percentage giving a positive response to feeling fatigue/sleepy after sleep and feeling 
sleepy/fatigued during the day were similar (46.0%, 46.9%). It is possible that COPD 
subjects present with similar symptoms of daytime sleepiness and fatigue as subjects with 
OSA originating from different etiologies. 
It is conceivable that subjects identified as negative from the Berlin sleep 
questionnaire was the result of a treatment effect.  Compared to the false positive 
subjects, the false negatives subjects had a lower percentage of positive results for 
snoring questions as well as wake time sleepiness questions compared to the false 
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positive subjects (Appendix F). It is possible that given treatment is effective, symptoms 
have been alleviated therefor less indication of snoring and fatigue in the false negatives.  
Future studies could include individually examining the utility of the Berlin sleep 
questionnaire by pulmonary abnormalities (emphysema, chronic bronchitis) to evaluate 
its value in these populations as current research has shown the heterogeneity of COPD. 
It is reasonable that treatment prescribed or lack thereof for the different pulmonary 
abnormalities could impact sleep architecture leading to symptoms similar to those 
identified in OSA.  
Further examining the results from the Berlin questionnaire, it was important for 
us to consider whether respondent bias affected the validity of the questionnaire. Given 
the population of COPDGene it is plausible to think that sicker subjects could have sent 
the questionnaire back because they have poor sleep related to their pulmonary condition 
and not the result of OSA which would have the potential of biasing our results. We 
compared respondents to non-respondents of the Berlin sleep questionnaire and found 
that the respondents and non-respondents did not differ by GOLD stages, chronic 
bronchitis, emphysema, diabetes, or cardiovascular disease (Appendix E). Nonetheless, it 
was interesting to see that subjects who responded to the questionnaire had a greater 
proportion answering “yes” to having OSA (self-reported) when in fact they did not 
(OSA diagnosed by sleep study).    
Alternatively, given the differential misclassification noted in our study, it would 
be beneficial to develop a screening tool explicit to pulmonary disease subjects which has 
the ability to differentiate between symptoms related to OSA and varying pulmonary 
manifestations in order to accurately rule out OSA diagnosis in a pulmonary population. 
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A future screening tool could include questions explicit to various pulmonary 
abnormalities with improved differentiation between daytime sleepiness due to sleep 
fragmentation resulting from obstructive events or resulting from coughing at night as an 
example. A simple yet valid screening tool is the first step to reducing financial burden 
and adverse outcomes in this population thus improving public health.  
8.2. OSA AND PULMONARY ABNORMALITIES 
The second goal of this study was to examine the relationship between OSA and 
different pulmonary abnormalities. This study, for the first time, provided more detailed 
information regarding the relationship between OSA and COPD and described unique 
relationships between OSA and different pulmonary abnormalities. It also suggests that 
the association between OSA and COPD relate to specific characteristics of the disease 
process and not the general ‘epi’ phenomenon of common smoking related diseases. 
Subjects with chronic bronchitis had increased risk of OSA (OR= 2.68, 95% CI 1.09-
6.64, p<0.05); by sleep study adjusted for demographics, current smoking, FEV1pp and 
bronchodilator use and the risk estimate increased when evaluating moderate/severe OSA 
compared to no OSA (OR=3.68, 95% CI 1.08-12.26, p<0.05) in model adjusted for the 
same covariates. Additionally, there was a significant trend of chronic bronchitis 
prevalence across severity of OSA (14.3%, 62.5%, 33.3% for mild OSA, moderate OSA, 
and severe OSA; p<0.0001).  
Possible explanations for our results could be the fact that pulmonary vascular 
remodeling in COPD has been shown to be related IL-18 [83] with expression as early as 
2 days of hypoxia and have been shown to be greater in subjects with chronic bronchitis 
[83] as well as subjects with OSA [206].  IL-18 is important as it is a pro inflammatory 
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cytokine that induces the production of TNF-α [90]. TNF-α has been shown in multiple 
studies to activate the NF-κB pathway leading to goblet cell metaplasia and mucus 
production in an IKKß dependent manner, however a difference in NF-κB pathway 
activity has not been observed between healthy smokers and smokers with COPD [83] 
resulting in lack of role of NF-κB pathway in COPD pathogenesis. Contrarily, the NF-κB 
pathway has been well studied in its role in hypoxic mediated inflammation where 
studies have found a selective and dose dependent activation of inflammatory pathways 
(NF-kB) from intermittent over chronic hypoxia [37].   
The lack of association between OSA, emphysema and GOLD stages 2-4 could 
be the protective relationship hypothesized between OSA and COPD. Animal data have 
suggested that thoracic inflation increases airway pharyngeal size and stiffness through 
caudal traction on the trachea independently of upper airway muscle activity. In 
obstructive lung disease such as emphysema, the lungs are hyperinflated indicated by 
high volume measures (total lung capacity, functional residual capacity, and residual 
volume). In our study we found that subjects with OSA had lower total lung capacity 
compared to subjects without OSA (TLC in OSA 5.65 compared to 6.08 in non OSA 
subjects; p<0.05; Chapter 5, Table 5.5). Exploring further we found that TLC was not 
different among different severities of OSA. Had there been a true protective relationship 
we would have expected there to be reduced TLC in subjects with more severe OSA. In 
addition, we did not see a significant trend of reduced prevalence of emphysema or 
GOLD stages 2-4 across severities of OSA which would be expected if a true protective 
relationship existed.  
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8.3. OSA AND SUBCLINICAL ATHEROSCLEROSIS 
The third goal of this study was to examine the relationship between OSA and 
coronary and thoracic calcium measures and further determine if the different pulmonary 
abnormalities influence the relationship. Our study demonstrated that OSA was 
associated with CAC independent of demographics, current smoking, emphysema, high 
blood pressure and diabetes in adjusted models (OR= 3.65, 95% CI=1.02-13.09, p<0.05) 
for sleep study diagnosed OSA, respectively. Further evaluating the influence of 
pulmonary abnormalities on the relationship between OSA and CAC there was a 
statistically significant interaction between OSA and chronic bronchitis. Our study found 
that there was no statistically significant association between OSA and TAC (OR=3.28, 
95% CI=0.82-13.15, p=0.0933) in adjusted models. These results indicate that OSA is 
related to subclinical atherosclerosis which is modified by one specific pulmonary 
abnormality, chronic bronchitis, and that the relationship may be unique to the coronary 
vascular bed.  
Given hypoxic medicated inflammation has been hypothesized as a pathway 
leading to atherosclerosis, we evaluated oxygenation measures and found that time spent 
below SpO2 88% was positively correlated with CAC (r = 0.42, p<0.05) and TAC (r = 
0.60, p<0.01, Chapter 6; Table 6.9.) although there was a greater correlation with TAC. 
There was a modest inverse correlation between lowest SpO2 during the sleep study and 
CAC (r = -0.39, p<0.05). Future studies could include utilizing the longitudinal data 
collection currently underway with COPDGene. Now that we have identified subjects 
with and without OSA at the National Jewish clinical center, we could follow these two 
groups and look for incident CAC. Additionally, we could use the longitudinal data to 
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look at CAC progression over time and see whether treatment with positive airway 
pressure therapy reduces CAC progression as studies have shown that continuous 
positive airway pressure reduces inflammation [50-55]. Of course a caveat will be 
whether subjects who have been prescribed treatment are compliant with their treatment 
on a nightly basis.  
8.4. RE-SATURATION 
The fourth goal of our study was to develop a novel variable of re-saturation 
collected by the actual polysomnogram and further determine if there is a difference in 
re-saturation time by subjects with OSA compared to subjects with OSA and pulmonary 
disease. In the preliminary results from our pilot study, we were the first to develop and 
document that re-saturation time for each event does not vary within subjects despite 
differences in event type and REM versus non REM sleep. Secondly, we were able to 
show that within OSA, subjects with concurrent emphysema have a much slower re-
saturation time as compared to subjects with OSA alone (p=0.02).  
Comparing subjects with OSA alone and OSA with chronic bronchitis, re-
saturation times were very similar (Figure 7.2). The results were not surprising as 
subjects with emphysema have destruction of alveoli leading to less area available for gas 
exchange thus reduction in diffusion capacity of the lungs [64] which we hypothesized to 
result in slower re-saturation times in subjects with both OSA and emphysema. Although 
we identified certain relationships between oxygenation measures and coronary and 
thoracic calcium, we plan to evaluate the correlation between the re-saturation variable 
and coronary calcium measures further evaluating whether this variable has better 
correlation with calcification measures compared to existing oxygenation measures (time 
 
                                                                                            115 
 
spent below 88%, and low SpO2) and if we are not limited by sample size, execute 
multivariable regression models to evaluate independent associations adjusting for the 
effects of confounding variables. The re-saturation variable has great potential for future 
use in further evaluating the hypoxic pathway leading to atherosclerotic CVD by looking 
at different inflammatory markers and determining if re-saturation in fact has increased 
presence of inflammatory markers such as TNF-α compared to other oxygenation 
variables.  Future studies in larger populations are needed to validate the results from our 
re-saturation study and provide more in depth analyses which is possible in the 
COPDGene cohort by including additional centers with available sleep records on 
COPDGene specific subjects. This is a very important study as hypoxemia from OSA can 
impact atherosclerotic development through inflammation [12] specifically inflammatory 
damage resulting from the re-saturation phase of the hypoxic event [39-43] and the 
physiologic SpO2 signal from a polysomnogram offers a simple way to measure re-
saturation in this population and could easily be programmed and offered as a summary 
measure on a polysomnographic report.  
This study is not without limitations. First, the study was only done in a small 
convenience sample from a single site of the larger COPDGene cohort with existing 
polysomnographic records available at National Jewish Health. Due to the small sample, 
we were not able to conduct statistical modeling adjusting for possible confounding 
variables. However, we did take a look at the characteristics between the groups to see if 
any of the variables had the potential to influence the results.  
In summary, the relationships between OSA and COPD are complicated and not 
the result of the general phenomenon previously suggested; the association is strictly due 
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to both disorders being smoking related diseases. OSA is related to specific pulmonary 
abnormalities, e.g. chronic bronchitis, and is not associated with emphysema in this 
study. OSA is associated with subclinical atherosclerosis, but this association is modified 
by pulmonary abnormalities with each condition’s individual or joint influence in 
development of subclinical coronary atherosclerosis. Compiling results from our studies 
in addition to research that has already been documented, it is plausible to think that there 
is a direct causal relationship between OSA and chronic bronchitis mediated through 
hypoxia with hypoxia triggering an inflammatory response with production of mucus 
primary to chronic bronchitis exceeding the effects of smoking. Further, due to elevation 
in inflammatory markers found in both OSA and chronic bronchitis (IL-18), it is possible 
that the presence of chronic bronchitis in subjects with OSA will have an additive effect 
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Male / Female    
 








































1. Has your weight changed? 
  Increased 
   Decreased 
  No Change 
 
2. Do you snore? 
  Yes 
  No 
  Don’t know 
 
If you snore: 
3. Your snoring is: 
  Slightly louder than breathing 
  As loud as talking 
  Louder than talking 




4. How often do you snore? 
  Nearly every day 
  3-4 times a week 
  1-2 times a week 
  1-2 times a month 
  Never or nearly never 
 
5. Has your snoring ever bothered 
other people? 
  Yes 
  No 
  Don’t Know 
 
6. Has anyone noticed that you 
quit 
breathing during your sleep? 
  Nearly every day 
  3-4 times a week 
  1-2 times a week 
  1-2 times a month 




7. How often do you feel tired or 
fatigued after your sleep? 
  Nearly every day 
  3-4 times a week 
  1-2 times a week 
  1-2 times a month 
  Never or nearly never 
 
8. During your waking time, do 
you feel tired, fatigued, or not up 
to par? 
  Nearly every day 
  3-4 times a week 
  1-2 times a week 
  1-2 times a month 
  Never or nearly never 
 
9. Have you ever nodded off or 
fallen asleep while driving a 
vehicle? 
  Yes 
  No 
 
If yes: 
10. How often does this occur? 
  Nearly every day 
  3-4 times a week 
  1-2 times a week 
  1-2 times a month 
  Never or nearly never 
 
CATEGORY 3 
11. Do you have high blood 
pressure? 
  Yes 
  No 
  Don’t know 
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Questionnaire adapted from: Table 2, Netzer, et al., 1999. (Netzer NC, Stoohs RA, Netzer   
CM,Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the   
sleep apnea syndrome. Ann Intern Med. 1999 Oct 5;131(7):485-91). 
 
Additional Questions 
12. Has a physician ever diagnosed 
you with sleep apnea? 
          Yes 
          No 
          Don’t know 
 
If yes to question 12, please answer 
13-15 otherwise stop here: 
13. Are you being treated with a 
positive airway pressure device? 
(e.g.: CPAP, BiPAP) 
  Yes 
  No 
 
14. Have you had surgery for your 
sleep apnea?   
  Yes 
  No 
If yes please indicate type of surgery 
below (eg: gastric bypass, UPPP, etc)  
____________________________ 
 
15. Do you use a dental device for 
your sleep apnea? (Oral appliance) 
  Yes 
  No 
 
16. Is there a possibility that you 
could be pregnant now?  
 
  Yes 









TABLE NUMBERS OF HIGH RISK OSA IDENTIFIED BY BERLIN 
QUESTIONNAIRE COMPARED TO POLYSOMNOGRAPHY  
BY COPD CASE STATUS 
 
n=335 






High Risk OSA 24 66 










High Risk OSA 10 28 










High Risk OSA 10 26 
Low Risk OSA 8 67 
 




TABLE NUMBERS OF SELF-REPORTED OSA COMPARED TO 









OSA+ 63 51 










OSA+ 30 25 
OSA- 18 121 









OSA+ 18 11 









CHARACTERISTICS OF BERLIN SLEEP QUESTIONNAIRE RESPONDENTS 
 
 
                      














Age, mean ± SD 63.17 ± 8.60 61.90 ± 9.00 <0.05 
Gender, n (% Male) 166 (50.15) 290 (48.82) NS 
Race, n (% Caucasian) 309 (93.35) 533 (89.73) NS 
Smoking,  n (% Current) 88 (26.59) 200 (33.67) <0.05 
Pack Years, mean ± SD 47.32 ± 44.40 46.12 ± 44.19 NS 
Emphysema, n (% Yes) 104 (39.25) 176 (36.90) NS 
Chronic Bronchitis, n (% Yes) 34 (17.44) 67 (18.21) NS 
GOLD stages 2-4, n (% Yes) 161 (59.19) 297 (60.61) NS 
Diabetes, n (% Yes) 49 (14.80) 67 (11.28) NS 
OSA1, n (% Yes) 57 (17.01) 41 (64.06) <0.0001 
OSA2, n (% Yes) 76 (22.96) 94 (15.82) <0.01 
CVD, n (% Yes) 64 (19.34) 106 (17.88) NS 
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APPENDIX E 
CORRELATIONS BETWEEN ADDITIONAL PULMONARY  
AND SLEEP MEASURES 
 
 FEV1pp FVCpp FEV1/FVC Emphysema 














r = -0.15 
p=0.2287 
n=69 
r = -0.24 
p<0.05 
n=69 
r = 0.03 
p=8247 
n=69 





r = 0.02 
p=0.9188 
n=24 
r = - 0.09 
p=0.6815 
n=24 
r = 0.17 
p=0.4348 
n=24 
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APPENDIX F 
DIFFERENCES IN BERLIN QUESTIONNAIRE RESPONSES  
BY MISCLASSIFIED SUBJECTS 
 
 
